Package Rates

BARIATRIC SURGERY
CARDIOLOGY
CARDIOTHORACIC SURGERIES
இருதய நோய் அறுவை சிகிச்சை
DERMATOLOGY
E N T
காது மூக்கு தொண்டை சிகிச்சை
ENDOCRINE SURGERY
ENDOCRINOLOGY
உட்சுரப்பி சிகிச்சை
GASTROENTEROLOGY
GENERAL MEDICINE
பொது மருத்துவ சிகிச்சை
GENERAL SURGERY
பொது அறுவை சிகிச்சை
GENITOURINARY SURGERY
இருபாலார் சிறுநீரக நோய் சிகிச்சை
GYNAECOLOGY OBSTETRIC SURGERY
இரத்தவகை சிகிச்சை
HEMATOLOGY
இரத்தவகை சிகிச்சை
HEPATOLOGY
கல்லீரல் நோய் சிகிச்சை
INFECTIOUS DISEASES - GENERAL MEDICINE
INTERVENTIONAL CARDIOLOGY
இடையீடு இருதயவியல்
INTERVENTIONAL RADIOLOGY
இடையீடு கதிர்வீச்சு இருதய சிகிச்சை
MEDICAL GASTROENTROLOGY
MEDICAL ONCOLOGY
புற்றுநோய் மருத்துவ சிகிச்சை
NEONATOLOGY
பச்சிளம் குழந்தைகள் சிகிச்சை
NEPHROLOGY
NEUROLOGY
நரம்பியல் சிகிச்சை
NEUROSURGERY
நரம்பியல் அறுவை சிகிச்சை
OFMS
வாய் வழி மற்றும் தாடை அறுவை சிகிச்சை
OPHTHALMOLOGY SURGERIES
கண் நோய் அறுவை சிகிச்சை
ORTHOPEDICS
எலும்பியல் காயம்
PAEDIATRIC INTENSIVE CARE
குழந்தைகளுக்கான தீவிர சிகிச்சை
PAEDIATRIC SURGERIES
குழந்தைகளுக்கான அறுவை சிகிச்சை
PAEDIATRICS
குழந்தை மருத்துவம்
PAIN & PALLIATION
கடைநிலை மருத்துவம்
PLASTIC SURGERY
ஒட்டுறுப்பு அறுவை சிகிச்சை
POLYTRAUMA
PSYCHIATRY
மனநல மருத்துவம்
PULMONLOGY
நுரையீரல் நோய்
RADIATION ONCOLOGY
கதிர்வீச்சு புற்றுநோய்
REHABILITATION
RHEUMATOLOGY
முடக்கு வாதம்
SPINE
SURGICAL GASTRO ENTEROLOGY
இரையகக் குடலியவியல்
SURGICAL ONCOLOGY
புற்றுநோய் அறுவைசிகிச்சை
THORACIC MEDICINE
VASCULAR SURGERIES
நாளஞ்சார் அறுவை சிகிச்சைகள்

SNOPackage NameCategoryA1A2A3A4 A5A6S1S2
3676 CMU0106 : BREAST CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3677 CMU0106 -a : BREAST CANCER - COMBINED REGIMEN AC & T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3678 CMU0106 -a-I : BREAST CANCER - DOSE DENSE AC (ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; (DAY 1 - DOXORUBICIN 60MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV) ; REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES; FOLLOWED BY PACLITAXEL FOR 4 CYCLES MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
3679 CMU0106 -a-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
3680 CMU0106 -a-III : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
3681 CMU0106 -a-IV : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 80MG/M2) REPEAT CYCLE - WEEKLY FOR 12 CYCLES MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3682 CMU0106 -b : BREAST CANCER - TC (DOECTAXEL & CYCLOPHOSPHAMIDE) ; DAY 1 - DOCETAXEL 75MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
3683 CMU0106 -c : BREAST CANCER - CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/FLUOROURACIL) - (INCLUDES DAY 1 & DAY 8) ; DAYS 1-14 - CYCLOPHOSPHAMIDE 100MG/M2 ORALLY ; DAYS 1 AND 8 - METHOTREXATE 40MG/M2 IV ; DAYS 1 AND 8 - 5-FLUOROURACIL 600MG/M2 IV. ; REPEAT CYCLE - EVERY 28 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
3684 CMU0106 -d : BREAST CANCER - EC (EPIRUBICIN/CYCLOPHOSPHAMIDE) ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 830MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 8 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
3685 CMU0106 -e : BREAST CANCER - FEC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3686 CMU0106 -e-I : BREAST CANCER - FEC/CEF FOLLOWED BY T (FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY DOCETAXEL OR FOLLOWED BY WEEKLY PACLITAXEL) ; DAY 1 - 5-FLUOROURACIL 500MG/M2 IV ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
3687 CMU0106 -e-II : BREAST CANCER - DOCETAXEL - (PRECEEDED BY FEC/CEF ) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3688 CMU0106 -e-III : BREAST CANCER - PACLITAXEL - WEEKLY - (PRECEEDED BY FEC/CEF ) ; PACLITAXEL 100MG/M2 IV ; REPEAT CYCLE - ONCE WEEKLY FOR 8 WEEKS MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3689 CMU0106 -f : BREAST CANCER - FAC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3690 CMU0106 -f-I : BREAST CANCER - FAC FOLLOWED BY T (FLUOROURACIL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY WEEKLY PACLITAXEL ; 5-FLUOROURACIL 500MG/M2 IV DAYS 1 AND 8 OR 1 AND 4 - ; DAY 1 - DOXORUBICIN 50MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
3691 CMU0106 -f-II : BREAST CANCER - PACLITAXEL - WEEKLY - PRECEEDED BY FAC ; PACLITAXEL 80MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3692 CMU0106 -g : BREAST CANCER - TAC (DOCETAXEL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
3693 CMU0106 -h : BREAST CANCER - AC FOLLOWED BY T + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3694 CMU0106 -h-I : BREAST CANCER - AC - FOLLOWED BY PACLITAXEL + TRASTUZUMAB +/- PERTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLE MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
3695 CMU0106 -h-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY AC) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3696 CMU0106 -h-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH PACLITAXEL CYCLE 1, 4, 7, 10 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3697 CMU0106 -h-IV : BREAST CANCER - TRASTUZUMAB 4MG (FOLLOWED BY TRASTUZUMAB 2MG SUBSEQUENT WEEKS) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3698 CMU0106 -h-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY TILL ONE YEAR FROM DAY 1 OF AC. ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12 AND STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3699 CMU0106 -i : BREAST CANCER - TCH MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3700 CMU0106 -i-I : BREAST CANCER - TC (DOCETAXEL/CARBOPLATIN) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CARBOPLATIN AUC 6MG PER MIN/ML IV. ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3701 CMU0106 -i-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH TC CYCLE 1 TO 6 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 18 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3702 CMU0106 -i-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH TC CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3703 CMU0106 -i-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES - WEEKLY) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 17 WEEEKS MAY OVERLAP WITH TC CYCLES 2 - 6. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3704 CMU0106 -j : BREAST CANCER - AC FOLLOWED BY DOCETAXEL + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3705 CMU0106 -j-I : BREAST CANCER - AC - FOLLOWED BY DOCETAXEL + TRASTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
3706 CMU0106 -j-II : BREAST CANCER - DOCETAXEL (PRECEEDED BY AC) + TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
3707 CMU0106 -j-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS TILL 1 YEAR ; (TO BE APPROVED WITH DOCETAXEL CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) OR FROM 13 TH WEEK AFTER COMPLETION OF 12 WEEKS OF WEEKLY TRASTUZUMAB - UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3708 CMU0106 -j-IV : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3709 CMU0106 -j-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3710 CMU0106 -k : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3711 CMU0106 -k-I : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE - WITH TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
3712 CMU0106 -k-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; (TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3713 CMU0106 -k-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3714 CMU0106 -k-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3715 CMU0106 -L : BREAST CANCER - PACLITAXEL + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3716 CMU0106 -L-I : BREAST CANCER - PACLITAXEL - (WITH TRASTUZUMAB) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
3717 CMU0106 -L-II : BREAST CANCER - TRASTUZUMAB (6MG) ; TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS ; (TO BE APPROVED AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3718 CMU0106 -L-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
3719 CMU0106 -L-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12. MAY BE APPROVED AS STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK OR TRASTUZUMAB 6MG PACKAGE MAY BE USED ONCE EVERY 21 DAYS UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3720 CMU0106 -N : BREAST CANCER - TAMOXIFEN MEDICAL ONCOLOGY 100 100 100 100 100 100 100 100
3721 CMU0106 -O : BREAST CANCER - AROMATASE INHIBITORS MEDICAL ONCOLOGY 1100 1100 1100 1100 1100 1100 1100 1100
3722 CMU0106 -P : BREAST CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
3723 CMU0107 : BLADDER CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3724 CMU0107 -a-I : BLADDER CANCER - DDMVAC ; DAY 1 - METHOTREXATE 30MG/M2 IV; DAY 2 - VINBLASTINE 3MG/M2 IV, DOXORUBICIN 30MG/M2 IV, CISPLATIN 70MG/M2 IV; ; REPEAT EVERY 2 WEEKS FOR 3-4 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3725 CMU0107 -a-II : BLADDER CANCER - GEMCITABINE + CISPLATIN ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV; DAY 2 - CISPLATIN 70MG/M2. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
3726 CMU0107 -a-III : BLADDER CANCER - CISPLATIN + METHOTREXATE + VINBLASTINE (CMV) ; DAY 1 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV; DAY 2 - CISPLATIN 100MG/M2 IV, LEUCOVORIN 15MG ORAL OR IV EVERY 6 HOURS FOR 4 DOSES; DAY 8 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV DAY 9 - LEUCOVORIN 15MG ORAL EVERY 6 HOURS FOR 4 DOSES ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
3727 CMU0107 -a-IV : BLADDER CANCER - RADIOSENSITIZING - CISPLATINC + 5-FU ; DAYS 1, 2, 3, 15, 16, AND 17 - IV HYDRATION AT A RATE OF 500ML/HOUR; FOLLOWED BY 5-FU 400MG/M2 IV PUSH; FOLLOWED BY CISPLATIN 15MG/M2 IV OVER 1 HOUR AS INDUCTION AND CONSOLIDATION THERAPY MEDICAL ONCOLOGY 10300 10300 10300 10300 10300 10300 10300 10300
3728 CMU0107 -a-V : BLADDER CANCER -RADIOSENSITIZING - CISPLATIN + PACLITAXEL ; DAYS 1, 8, AND 15 - PACLITAXEL 50MG/M2 ; DAY 1-3, 8-10, 15-17 - CISPLATIN 15MG/M2; FOLLOWED BY TWICE-DAILY RADIOTHERAPY FOR 8 DAYS MEDICAL ONCOLOGY 19300 19300 19300 19300 19300 19300 19300 19300
3729 CMU0107 -a-VI : BLADDER CANCER -RADIOSENSITIZING - 5-FU + MITOMYCIN32 ; DAY 1 OF RADIOTHERAPY - MITOMYCIN 12MG/M2 IV BOLUS, PLUS ; WEEK 1 (FRACTIONS 1-5) AND WEEK 4 (FRACTIONS 16-20) OF RADIOTHERAPY - 5-FU 500MG/M2 CONTINUOUS IV INFUSION (10 DAYS TOTAL) MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
3730 CMU0107 -c : BLADDER CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3731 CMU0108 : LUNG CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3732 CMU0108 -i : LUNG CANCER - MESOTHELIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3733 CMU0108 -i-a : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CISPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CISPLATIN 75MG/M2 ; REPEAT EVERY 21 DAYS UP TO 12 CYCLES. MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
3734 CMU0108 -i-b : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CARBOPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CARBOPLATIN AUC 5MG/MIN/ML IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 9 CYCLES. MEDICAL ONCOLOGY 17300 17300 17300 17300 17300 17300 17300 17300
3735 CMU0108 -i-c : LUNG CANCER - MESOTHELIOMA - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 80-100MG/M2 IV ; DAYS 1, 8, AND 15 - GEMCITABINE 1000-1250MG/M2 IV ; REPEAT EVERY 21 - 28 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
3736 CMU0108 -i-d : LUNG CANCER - MESOTHELIOMA - VINORELBINE ; VINORELBINE 25-30MG/M2 (MAX 60MG) IV ; REPEAT EVERY WEEK FOR 12 WEEKS. MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
3737 CMU0108 -i-e : LUNG CANCER - MESOTHELIOMA - PEMETREXED ; DAY 1 - PEMETREXED 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR 4 CYCLES (IF FIRST LINE) OR REPEAT EVERY 21 DAYS FOR 8 CYCLES (IF SECOND LINE) MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
3738 CMU0108 -i-f : LUNG CANCER - MESOTHELIOMA - GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 28 DAYS FOR A MAX OF 10 CYCLES. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
3739 CMU0108 -ii : LUNG CANCER - NSCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3740 CMU0108 -ii-a : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (I) ; DAYS 1 AND 8 - CISPLATIN 50MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 25MG/M2 IV ; (OR) ; DAY 1 - CISPLATIN 100MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 30MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 35300 35300 35300 35300 35300 35300 35300 35300
3741 CMU0108 -ii-b : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (II) ; DAY 1 - CISPLATIN 75-80MG/M2 ; DAYS 1 AND 8 - VINORELBINE 25-30MG/M2. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 18800 18800 18800 18800 18800 18800 18800 18800
3742 CMU0108 -ii-c : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
3743 CMU0108 -ii-d : LUNG CANCER - NSCLC - CISPLATIN & DOCETAXEL ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
3744 CMU0108 -ii-e : LUNG CANCER - NSCLC - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 1 AND 8 - GEMCITABINE 1, 250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 6400 6400 6400 6400 6400 6400 6400 6400
3745 CMU0108 -ii-f : LUNG CANCER - NSCLC - PEMETREXED + CISPLATIN (FOR NON SQUAMOUS CELL CA) ; DAY 1 - CISPLATIN 75MG/M2 IV, PEMETREXED 500MG/M2 IV. ; REPEAT EVERY - 21 DAYS FOR 4 CYCLES. MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
3746 CMU0108 -ii-g : LUNG CANCER - NSCLC - PACLITAXEL/CARBOPLATIN ; DAY 1 - PACLITAXEL 200MG/M2 IV, CARBOPLATIN AUC 6MG PER MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
3747 CMU0108 -ii-h : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAYS 1, 8, 29 AND 36 - CISPLATIN 50MG/M2 IV ; DAYS 1-5 AND 29-33 - ETOPOSIDE 50MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY 1.8GY/DAY FOR 5 DAYS/WEEK (TOTAL DOSE, 61GY). MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
3748 CMU0108 -ii-i : LUNG CANCER - NSCLC - CISPLATIN & VINBLASTINE ; DAYS 1 AND 29 - CISPLATIN 100MG/M2 IV ; DAYS 1, 8, 15, 22 AND 29 - VINBLASTINE 5MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY). MEDICAL ONCOLOGY 8600 8600 8600 8600 8600 8600 8600 8600
3749 CMU0108 -iii : LUNG CANCER - SCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3750 CMU0108 -iii-a : LUNG CANCER - SCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 60MG/M2 IV, DAYS 1-3 - ETOPOSIDE 120MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR AT LEAST 4 CYCLES. ;(OR) ; DAY 1 - CISPLATIN 80MG/M2 IV, DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4-6 CYCLES. MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
3751 CMU0108 -iii-b : LUNG CANCER - SCLC - CARBOPLATIN & ETOPOSIDE ; DAY 1 - CARBOPLATIN AUC 5-6MG PER MIN/ML IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS OR 28 DAYS FOR 4 - 6 CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
3752 CMU0108 -iii-c : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
3753 CMU0108 -iii-d : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 AND 8 - CISPLATIN 30MG/M2 IV, IRINOTECAN 65MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4-6 CYCLES. MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
3754 CMU0108 -iii-e : LUNG CANCER - SCLC - CARBOPLATIN & IRINOTECAN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 50MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
3755 CMU0108 -ii-j : LUNG CANCER - NSCLC - CARBOPLATIN + PEMETREXED ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 17300 17300 17300 17300 17300 17300 17300 17300
3756 CMU0108 -ii-k : LUNG CANCER - NSCLC - CISPLATIN + PEMETREXED ; DAY 1 - CISPLATIN 75 MG/M2 IV. ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 15700 15700 15700 15700 15700 15700 15700 15700
3757 CMU0108 -ii-l : LUNG CANCER - NSCLC - PACLITAXEL + CARBOPLATIN ; PACLITAXEL 45MG/M2 IV + CARBOPLATIN AUC 2MG PER MIN/ML IV ; WITH CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY) ; REPEAT WEEKLY FOR 6 WEEKS MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
3758 CMU0109 : OESOPHAGEAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3759 CMU0109 -i : ESOPHAGEAL CANCER - NEO ADJUVANT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3760 CMU0109 -i-a : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV + CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
3761 CMU0109 -i-b : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV. MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
3762 CMU0109 -i-c : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 AND DAYS 22-26 - 5-FU 800 MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3763 CMU0109 -i-d : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL + OXALIPLATIN + LEUCOVORIN ; DAY 1 - OXALIPLATIN 85MG/M2, LEUCOVORIN 200MG/M2 AND 5-FU 400MG/M2 BOLUS, WITH 1, 600MG/M2 INFUSION; ; REPEAT EVERY 14 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
3764 CMU0109 -i-e : ESOPHAGEAL CANCER - NEO ADJUVANT - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
3765 CMU0109 -i-f : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
3766 CMU0109 -i-g : ESOPHAGEAL CANCER - NEO ADJUVANT - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS. MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3767 CMU0109 -i-h : ESOPHAGEAL CANCER - NEO ADJUVANT - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV, CISPLATIN 30MG/M2 IV. MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
3768 CMU0109 -i-i : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV INFUSION. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3769 CMU0109 -ii : ESOPHAGEAL CANCER - PERI-OPERATIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3770 CMU0109 -ii-a : ESOPHAGEAL CANCER - PERI-OPERATIVE - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV CONTINUOUS INFUSION ONCE DAILY; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
3771 CMU0109 -ii-b : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 19700 19700 19700 19700 19700 19700 19700 19700
3772 CMU0109 -ii-c : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOC (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
3773 CMU0109 -ii-d : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-4 CYCLES MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
3774 CMU0109 -ii-e : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLESCYCLED EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3775 CMU0109 -iii : ESOPHAGEAL CANCER - POST-OPERATIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3776 CMU0109 -iii-a : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (I) ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV, FOLLOWED BY 4 WEEKS BREAK AND CCRT ; RT DAYS 1-4 AND 23-25 - 5-FU 400MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV. MEDICAL ONCOLOGY 26700 26700 26700 26700 26700 26700 26700 26700
3777 CMU0109 -iii-b : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 200MG/M2 IV, 5-FU 400MG/M2 IV PUSH AND 5-FU 600MG/M2 INFUSION MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
3778 CMU0109 -iii-c : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY; ; REPEAT EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
3779 CMU0109 -iii-d : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY, ; ONCE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
3780 CMU0109 -iii-e : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACILDAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS DAILY, ; ONCE WEEKLY FOR 5 WEEKS.ONCE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
3781 CMU0109 -i-j : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
3782 CMU0109 -iv : ESOPHAGEAL CANCER - DEFINITIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3783 CMU0109 -iv-a : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
3784 CMU0109 -iv-b : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3785 CMU0109 -iv-c : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY CONTINUOUS IV INFUSION. MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
3786 CMU0109 -iv-d : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
3787 CMU0109 -iv-e : ESOPHAGEAL CANCER - DEFINITIVE - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3788 CMU0109 -iv-f : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV AND CARBOPLATIN 2MG/MIN/ML IV ; REPEAT WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
3789 CMU0109 -iv-g : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (I) ; DAYS 1 AND 22 - DOCETAXEL 60MG/M2 IV ; DAYS 1 AND 22 - CISPLATIN 60-80MG/M2 IV GIVEN FOR 1 CYCLE MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3790 CMU0109 -iv-h : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (II) ; DAY 1 - DOCETAXEL 20-30MG/M2 IV ; DAY 1 - CISPLATIN 20-30MG/M2 IV ; REPEAT WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
3791 CMU0109 -iv-i : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH PACLITAXEL ; DAYS 1, 8, 15, AND 22 - PACLITAXEL 60MG/M2 IV ; DAY 1 - CISPLATIN 75MG/M2 IV GIVEN FOR 1 CYCLE. MEDICAL ONCOLOGY 13800 13800 13800 13800 13800 13800 13800 13800
3792 CMU0109 -iv-j : ESOPHAGEAL CANCER - DEFINITIVE - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV ; DAYS 1, 8, 22, AND 29 - CISPLATIN 30MG/M2 IV. MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
3793 CMU0109 -iv-k : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3794 CMU0109 -iv-l : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 PO TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
3795 CMU0109 -v : ESOPHAGEAL CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3796 CMU0110 : GASTRIC CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3797 CMU0110 -i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3798 CMU0110 -i-a : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV, CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
3799 CMU0110 -i-b : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1000MG/M2/DAY IV MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
3800 CMU0110 -i-c : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV ONCE DAILY, 5-FU 800MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 2 CYCLES. MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3801 CMU0110 -i-d : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (I)DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV. MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
3802 CMU0110 -i-e : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (II)DAY 1 - OXALIPLATIN 85MG/M2 AND LEUCOVORIN 400MG/M2 FOLLOWED BY 5-FU 400MG/M2 BOLUS, THEN 800MG/M2 24-HOUR CONTINUOUS INFUSION OVER DAYS 1 AND 2; THE FIRST 3 CYCLES WERE DELIVERED DURING RADIOTHERAPY (RT), THE OTHER 3 AFTER RT; 6 BIMONTHLY (14 DAYS) CYCLES. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
3803 CMU0110 -i-f : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
3804 CMU0110 -i-g : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3805 CMU0110 -i-h : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45-50MG/M2 IV WEEKLY ; DAYS 1-5 - 5-FU 300MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3806 CMU0110 -ii : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3807 CMU0110 -i-i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
3808 CMU0110 -ii-a : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV, CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
3809 CMU0110 -ii-b : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EOF (EPIRUBICIN/ OXALIPLATIN /FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 19300 19300 19300 19300 19300 19300 19300 19300
3810 CMU0110 -ii-c : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EPIRUBICIN + CISPLATIN + CAPECITABINE ; DAY 1 - EPIRUBICIN 50MG/M2 IV + CISPLATIN 60MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
3811 CMU0110 -ii-d : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF MODIFICATION (EPIRUBICIN + OXALIPLATIN + CAPECITABINE) ; DAY 1 - EPIRUBICIN 50MG/M2 IV + OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELYREPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
3812 CMU0110 -ii-e : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL & CISPLATIN ; DAY 1 - CISPLATIN 75-80MG/M2 IV ; DAYS 1-5 - 5-FU 800MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-3 CYCLES PREOPERATIVELY AND 3-4 CYCLES POSTOPERATIVELY FOR A TOTAL OF 6 CYCLES. MEDICAL ONCOLOGY 7300 7300 7300 7300 7300 7300 7300 7300
3813 CMU0110 -iii : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3814 CMU0110 -iii-a : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (I) ; CYCLES 1, 3, AND 4 (BEFORE AND AFTER RADIATION) DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2/DAY IV ; REPEAT CYCLE EVERY 28 DAYS. ; CYCLE 2 (WITH RADIATION) DAYS 1-4 AND 31-33 - LEUCOVORIN 20MG/M2 IVP ; DAYS 1-4 - 5-FU 400MG/M2/DAY IVP. ; REPEAT CYCLE EVERY 35 DAYS MEDICAL ONCOLOGY 26700 26700 26700 26700 26700 26700 26700 26700
3815 CMU0110 -iii-b : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV AND 5-FU 1200MG/M2 INFUSION; ; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. ; REPEAT CYCLE EVERY 28 DAYSREPEAT CYCLE EVERY 28 DAYS MEDICAL ONCOLOGY 15700 15700 15700 15700 15700 15700 15700 15700
3816 CMU0110 -iii-c : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
3817 CMU0110 -iii-d : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY; WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
3818 CMU0110 -iii-e : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL ; DAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV; ; WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
3819 CMU0110 -iii-f : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 4200 4200 4200 4200 4200 4200 4200 4200
3820 CMU0110 -iii-h : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - OXALIPLATIN + CAPECITABINE ; DAY 1 - OXALIPLATIN 130MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
3821 CMU0111 : COLORECTAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3822 CMU0111 -i : COLORECTAL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3823 CMU0111 -i-a : COLORECTAL CARCINOMA - FOLFOX (STAGE - III) - (OXALIPLATIN, LEUCOVORIN, 5-FU) ; DAY 1 - OXALIPLATIN 85MG/M2 IV, LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV, FOLLOWED BY 5-FU 1, 200MG/M2/DAY IV X 2 DAYS (TOTAL 2, 400MG/M2) OVER 46-48-HOUR CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS- UPTO 12 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
3824 CMU0111 -i-b : COLORECTAL CARCINOMA - CAPEOX (STAGE - III) (OXALIPLATIN, CAPECITABINE) ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAYS 1-14 - CAPECITABINE 1, 000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 MONTHS MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
3825 CMU0111 -i-c : COLORECTAL CARCINOMA - FLOX (STAGE - III) (5-FU, LEUCOVORIN, OXALIPLATIN) ; 5-FU 500MG/M2 IV BOLUS WEEKLY X 6, LEUCOVORIN 500MG/M2 IV WEEKLY X 6, EACH ; OXALIPLATIN 85MG/M2 IV ON WEEKS 1, 3, AND 5 ; 8-WEEK CYCLE X 3 CYCLES ; MEDICAL ONCOLOGY 31500 31500 31500 31500 31500 31500 31500 31500
3826 CMU0111 -i-d : COLORECTAL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKSL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKS MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
3827 CMU0111 -i-e : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (I) ; LEUCOVORIN 500MG/M2 WEEKLY X 6 WEEKS, ; 5-FU 500MG/M2 WEEKLY X 6 WEEKS. ; REPEAT CYCLE EVERY 8 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 24900 24900 24900 24900 24900 24900 24900 24900
3828 CMU0111 -i-f : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (II)SIMPLIFIED BIWEEKLY INFUSION. ; LEUCOVORIN 400MG/M2 IV, 5-FU BOLUS 400MG/M2 AND THEN 1, 200MG/M2/DAY X 2 DAYS (TOTAL 2, 400MG/M2 OVER 46-48 HOURS) ; REPEAT CYCLE EVERY 2 WEEKS FOR 6 CYCLES. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
3829 CMU0111 -ii : COLORECTAL CARCINOMA - CONCURRENT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3830 CMU0111 -ii-a : COLORECTAL CARCINOMA - CONCURRENT - 5FU - WITH XRT ; DAYS 1-5 OR 1-7 - 5-FU 225MG/M2 IV ; WITH EXTERNAL BEAM RADIOTHERAPY MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3831 CMU0111 -ii-b : COLORECTAL CARCINOMA - CONCURRENT - FLUOROURACIL + LEUCOVORIN - WITH XRT ; DAYS 1-4 - 5-FU 400MG/M2 IV + LEUCOVORIN 20MG/M2 IV. ; REPEAT CYCLE DURING WEEKS 1 AND 5 OF XRT. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
3832 CMU0111 -ii-c : COLORECTAL CARCINOMA - CONCURRENT - CAPECITABINE - WITH XRT ; CAPECITABINE TABLET 825MG / M2 TWICE DAILY ON DAYS 1-5 ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1400 1400 1400 1400 1400 1400 1400 1400
3833 CMU0112 : OSTEOSARCOMA/ BONE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3834 CMU0112 -i-a : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - CISPLATIN + DOXORUBICIN ; DAYS 1-3 - DOXORUBICIN 25MG/M2/DAY IV, ; DAY 1 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
3835 CMU0112 -i-b-1 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - PRE OPERATIVE ; DAYS 1 AND 28 - METHOTREXATE 8G/M2 IV ; DAYS 7-9 AND 34-36 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. ; DAYS 9 AND 36 - DOXORUBICIN 60MG/M2 IV MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
3836 CMU0112 -i-b-2 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS < 90% ; DAYS 1, 48, 96, AND 144 - DOXORUBICIN 45MG/M2/DAY FOR 2 CONSECUTIVE DAYS ; DAYS 21, 69, AND 117 - METHOTREXATE 8G/M2 IV ; DAYS 27, 75, AND 123 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. MEDICAL ONCOLOGY 42000 42000 42000 42000 42000 42000 42000 42000
3837 CMU0112 -i-b-3 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS > 90%POSTOPERATIVE CHEMOTHERAPY (NECROSIS MEDICAL ONCOLOGY 62000 62000 62000 62000 62000 62000 62000 62000
3838 CMU0112 -i-c : DOXORUBICIN + CISPLATIN + IFOSFAMIDE + HIGH-DOSE METHOTREXATE (INCLUDING SURGERY COST) MEDICAL ONCOLOGY 117100 117100 117100 117100 117100 117100 117100 117100
3839 CMU0112 -i-d : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - IFOSFAMIDE + CISPLATIN + EPIRUBICIN ; DAY 1 - EPIRUBICIN 90MG/M2 IV, CISPLATIN 100MG/M2 IV ; DAYS 2-4 - IFOSFAMIDE 2.0G/M2 WITH MESNA ; REPEAT CYCLE EVERY 21 DAYS. (3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY). MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
3840 CMU0112 -ii : OTHER BONE TUMORS - CHORDROMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3841 CMU0112 -ii-a : OTHER BONE TUMORS - CHORDROMA - IMATINIB ; IMATINIB 800 MG ONCE DAILY MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
3842 CMU0112 -ii-b : OTHER BONE TUMORS - CHORDROMA - IMATINIB + CISPLATIN ; IMATINIB 400MG OD + CISPLATIN 25MG/M2 WEEKLY. MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
3843 CMU0112 -ii-c : OTHER BONE TUMORS - CHORDROMA - IMATINIB + SIROLIMUS ; IMATINIB 400MG OD + SIROLIMUS 2MG OD MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
3844 CMU0112 -ii-d : OTHER BONE TUMORS - CHORDROMA - ERLOTINIB ; ERLOTINIB 150MG OD MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
3845 CMU0112 -ii-e : OTHER BONE TUMORS - CHORDROMA - SUNITINIB ; SUNITINIB 37.5MG OD MEDICAL ONCOLOGY 29900 29900 29900 29900 29900 29900 29900 29900
3846 CMU0112 -iii : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3847 CMU0112 -iii-a : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - DENOSUMAB ; DENOSUMAB 120MG SUBCUTANEOUS ON WEEK 1, 2 AND 3 OF A 4 WEEK CYCLE MEDICAL ONCOLOGY 58800 58800 58800 58800 58800 58800 58800 58800
3848 CMU0112 -iii-b : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - INTERFERON ALFA ; INTERFERON ALFA- 2A THRICE WEEKLY MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
3849 CMU0112 -iii-c : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - PEGINTERFERON ; PEGINTERFERON ALFA-2A 1.0MCG/KG SQ INJECTION WEEKLY. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3850 CMU0112 -iv : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3851 CMU0112 -iv-a : VAC AND IE CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
3852 CMU0112 -iv-b : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VAIA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
3853 CMU0112 -vi : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VIDE (VINCRISTINE + IFOSFAMIDE + DOXORUBICIN + ETOPOSIDE) ; DAY 1 - VINCRISTINE 1.4MG/M2 (MAX 2MG), ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV + IFOSFAMIDE 3MG/M2 IV + MESNA 3G/M2 + ETOPOSIDE 150MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
3854 CMU0113 : WILMS TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3855 CMU0113 -a : WILMS TUMOR - VINCRISTINE & ACTINOMYCIN D ; DACTINOMYCIN 45MCG/KG - WEEK - 0, 3, 6, 9, 12, 15, 18 ; VINCRISTINE 1.5 MG/M2 - WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18 MEDICAL ONCOLOGY 20400 20400 20400 20400 20400 20400 20400 20400
3856 CMU0113 -b : WILMS TUMOR - DACTINOMYCIN, VINCRISTINE & ADRIAMYCIN ; DACTINOMYCIN 1.35 MG /M2 - WEEK - 0, 6, 12, 18, 24 ; ADRIYAMYCIN 30-45 MG /M2- WEEK - 3, 9, 15, 21 ; VINCRISTINE 2MG MAX- WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 24 MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
3857 CMU0113 -c : WILMS TUMOR - ADRIAMYCIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 3, 9, 15, 21 FOR 5 DAYS, WEEK - 6, 12, 18, 24 FOR 3 DAYS ; ADRIYAMYCIN 30-45MG /M2- WEEK -0, 6, 12, 18, 24 ; VINCRISTINE 2MG (MAX)- WEEK - 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 18, 24 ; ETOPOSIDE 100MG /M2- WEEK - 3, 9, 15, 21 MEDICAL ONCOLOGY 56400 56400 56400 56400 56400 56400 56400 56400
3858 CMU0113 -d : WILMS TUMOR - CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 6, 15, 24 *5 DAYS / WEEK ; CARBOPLATIN 500MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *2 DAYS / WEEK ; ETOPOSIDE 100MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *5 DAYS / WEEK MEDICAL ONCOLOGY 88700 88700 88700 88700 88700 88700 88700 88700
3859 CMU0114 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3860 CMU0114 -a : HEPATOBLASTOMA- OPERABLE - PLADO - CISPLATIN + DOXORUBICIN ; CISPLATIN (PLA) (80MG/M2 / IV), DOXORUBICIN (DO) (30 MG/M2 IV ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
3861 CMU0114 -b : HEPATOBLASTOMA- OPERABLE - CISPLATIN + VINCRISTINE +5FU ; CISPLATIN (90 MG/M2), VINCRISTINE (1.5MG/M2), 5-FU(5-FLUROURACIL- 600 MG/M2) ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
3862 CMU0115 : HEPATOCELLULAR CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3863 CMU0115 -a : HEPATOCELLULAR CARCINOMA - SORAFENIB ; SORAFENIB 400 MG PO BID MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
3864 CMU0116 : NEUROBLASTOMA ALL STAGES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3865 CMU0116 A : NEUROBLASTOMA ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
3866 CMU0116 B : NEUROBLASTOMA ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300MG/M2 ; ADRIAMYCIN 60MG/M2 ; VINCRISTINE 1.5MG/M2 MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
3867 CMU0116 C : NEUROBLASTOMA ALL STAGES - CISPLATIN & ETOPOSIDE ; DAYS 1-5 - CISPLATIN - 20MG/M2 ; DAYS 1-5 - ETOPOSIDE - 70 MG/M2 MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
3868 CMU0116 D : NEUROBLASTOMA ALL STAGES - CARBOPLATIN & ETOPOSIDE ; DAYS 1-2 - CARBOPLATIN - 500MG/M2 ; DAYS 1-5 - ETOPOSIDE 100MG/M2 MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
3869 CMU0116 E : NEUROBLASTOMA ALL STAGES - FOR STAGE IV PALLIATIVE CHEMOTHERAPY ONLY MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
3870 CMU0117 : RETINOBLASTOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3871 CMU0117 -a : RETINOBLASTOMA - MELPHALAN - INTRA-ARTERIAL ; MELPHALAN - 3-7.5MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
3872 CMU0117 -b : RETINOBLASTOMA - CARBOPLATIN - INTRA-ARTERIAL ; CARBOPLATIN 15-30 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3873 CMU0117 -c : RETINOBLASTOMA - TOPOTECAN - INTRA-ARTERIAL ; TOPOTECAN 0.15-1.5 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
3874 CMU0117 -d : RETINOBLASTOMA - METHOTREXATE - INTRA-ARTERIAL ; METHOTREXATE 6-12 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 9100 9100 9100 9100 9100 9100 9100 9100
3875 CMU0117 -e : RETINOBLASTOMA - CARBOPLATIN - PERI OCULAR ; CARBOPLATIN 20MG/M2 - PERI OCULAR MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
3876 CMU0117 -f : RETINOBLASTOMA - TOPOTECAN - PERI OCULAR ; TOPOTECAN 0.09 - 0.27 - PERI OCULAR MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
3877 CMU0117 -g : RETINOBLASTOMA - MELPHALAN - INTRA-VITREAL ; MELPHALAN 20-30 MCG / 0.1CC - INTRA-VITREAL MEDICAL ONCOLOGY 300 300 300 300 300 300 300 300
3878 CMU0117 -h : RETINOBLASTOMA - CARBOPLATIN - INTRA-VITREAL ; CARBOPLATIN 3-6MCG / 0.05CC - INTRA-VITREAL MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
3879 CMU0117 -i : RETINOBLASTOMA - METHOTREXATE - INTRA-VITREAL ; METHOTREXATE 400MCG/0.1CC - INTRA-VITREAL MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
3880 CMU0117 -j : RETINOBLASTOMA - CARBOPLATIN + ETOPOSIDE + VINCRISTINE ; CARBOPLATIN 560MG/M2 ; ETOPOSIDE 150MG/M2 ; VINCRISTINE 1.5MG/M2 MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
3881 CMU0118 : HISTIOCYTOSIS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3882 CMU0118 -a : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 1; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
3883 CMU0118 -b : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 2; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
3884 CMU0118 -c : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - CONTINUATION; PREDNISOLONE AND VINBLASTINE - CONTINUATION AFTER EITHER COURSE 1 OR BOTH 1 & 2 ; PREDNISOLONE - 5 DAYS A WEEK ORAL ; VINBLASTINE -IV ; REPEAT EVERY 3 WEEKS TILL 1 YEAR MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3885 CMU0119 : RHABDOMYOSARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3886 CMU0119 -a : RHABDOMYOSARCOMA - VAC (VINCRISTINE + DACTINOMYCIN + CYCLOPHOSPHAMIDE + MESNA ) ; DAY -1 - VINCRISTINE 1.5 MG /M2 IV (2 MG MAX), DOXORUBICIN 75 MG /M2 IV, CYCLOPHOSPHAMIDE 1200 MG /M2 IV + MESNA ; REPEAT AT 21 DAY INTERVALS FOR 4-6 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3887 CMU0119 -b : RHABDOMYOSARCOMA - IVA (VINCRISTINE + DACTINOMYCIN + IFOSFAMIDE + MESNA ) ; DAY 1, 2 - IFOSFAMIDE IV 3 G/M2 + MESNA ; DAY 1 - VINCRISTINE IV 1.5 MG/M2 (MAX 2 MG), ACTINOMYCIN-D IV 1.5 MG/M2 (MAX 2 MG) ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
3888 CMU0119 -c : RHABDOMYOSARCOMA - IVAD (VINCRISTINE + DOXORUBICIN + IFOSFAMIDE + MESNA ) ; DAYS 1 AND 2 - IFOSFAMIDE 3 G/M2 + MESNA, DOXORUBICIN 30MG/M2 ; DAY 1 - VINCRISTINE 1.5 MG/M2, ACTINOMYCIN-D 1.5 MG/M2 ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3889 CMU0120 : EWINGS SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3890 CMU0120 -i : EWINGS SARCOMA - INDUCTION TREATMENT I MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3891 CMU0120 -i-a : EWINGS SARCOMA - INDUCTION TREATMENT - VIDE ; DAY 1 - VINCRISTINE 1.5MG/M2(MAX 2MG) IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV, IFOSFAMIDE 3G/M2IV, MESNA CONTINUOUS IV, ETOPOSIDE 150MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 8800 8800 8800 8800 8800 8800 8800 8800
3892 CMU0120 -i-b : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3893 CMU0120 -i-b-1 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - VAC ; DAY 1 - VINCRISTINE 2MG/M2 (MAX 2MG) IV, DOXORUBICIN 75MG/M2 IV BOLUS, CYCLOPHOSPHAMIDE 1, 200MG/M2 IV, MESNA. ; DACTINOMYCIN 1.25MG/M2 IV CAN BE SUBSTITUTED FOR DOXORUBICIN WHEN A TOTAL DOXORUBICIN DOSE OF 375MG/M2 IS REACHED. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
3894 CMU0120 -i-b-2 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - IE ; IE CYCLES ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2 IV + MESNA + ETOPOSIDE 100MG/M2 IV. ; REPEAT EACH CYCLE EVERY 3 WEEKS FOR 17 CYCLES. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
3895 CMU0120 -i-c : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 4 DAY REGIMEN ; DAY 1 - VINCRISTINE 1.5MG/M2IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, THEN LOCAL THERAPY, FOLLOWED BY 10 ADDITIONAL CYCLES OF VAIA FOR HIGH RISK AND ; 10 ADDITIONAL CYCLES OF VAIA OR 10 CYCLES OF VACA FOR STANDARD-RISK PATIENTS MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
3896 CMU0120 -i-d : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 24 DAY REGIMEN ; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1, 2, 22, 23, 43, AND 44 - IFOSFAMIDE 3, 000MG/M2 IV + MESNA ; DAYS 1, 2, 43, AND 44 - DOXORUBICIN 30MG/M2 IV ; DAYS 22, 23, AND 24 - DACTINOMYCIN 0.5MG/M2 IV ; AFTER COMPLETION OF ONE 9-WEEK CYCLE, LOCAL THERAPY FOLLOWED BY 3 ADDITIONAL CYCLES. MEDICAL ONCOLOGY 18600 18600 18600 18600 18600 18600 18600 18600
3897 CMU0120 -i-e : EWINGS SARCOMA - INDUCTION TREATMENT - VACA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + CYCLOPHOSPHAMIDE 1, 200MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 10 CYCLES. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
3898 CMU0120 -ii : EWINGS SARCOMA - MAINTENANCE TREATMENT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3899 CMU0120 -ii-a : EWINGS SARCOMA - MAINTENANCE TREATMENT - ETOPOSIDE/IFOSFAMIDE ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2/DAY IV + MESNA ; DAYS 1-5 - ETOPOSIDE 100MG/M2/DAY IV. MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
3900 CMU0121 : PALLIATIVE CHEMOTHERAPY (ANY REGIMEN)- MAXIMUM PAYABLE MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
3901 CMU0122 : CERVICAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3902 CMU0122 -a : CERVICAL CANCER - CISPLATIN ; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3903 CMU0122 -b : CERVICAL CANCER - CISPLATIN & 5FU WITH RT ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 IV OVER 96 HOURS ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
3904 CMU0122 -c : CERVICAL CANCER - CISPLATIN & 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
3905 CMU0123 : VULVAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3906 CMU0123 -a : VULVAL CANCER - CISPLATIN ; DAY 1 - 40 MG/M 2 IV MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3907 CMU0123 -b : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS - TOTAL 3 CYCLES MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
3908 CMU0123 -c : VULVAL CANCER - 5-FU + MITOMYCIN ; 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
3909 CMU0123 -e : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV MEDICAL ONCOLOGY 11700 11700 11700 11700 11700 11700 11700 11700
3910 CMU0124 : VAGINAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3911 CMU0124 -a : VAGINAL CANCER - CISPLATIN ; CISPLATIN 75MG/M2 ; ONCE WEEKLY FOR UP TO 6 DOSES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3912 CMU0125 : OVARIAN CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3913 CMU0125 -a : OVARIAN CANCER - PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 135MG/M2 CONTINUOUS IV ; DAY 2 - CISPLATIN 75-100MG/M2 ; DAY 8 - PACLITAXEL 60MG/M2 ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES. MEDICAL ONCOLOGY 9300 9300 9300 9300 9300 9300 9300 9300
3914 CMU0125 -b : OVARIAN CANCER - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML IV ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
3915 CMU0125 -c : OVARIAN CANCER - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 60-75MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
3916 CMU0126 : ENDOMETRIAL CANCER (PALLIATIVE CHEMOTHERAPY ONLY) MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
3917 CMU0127 : OVARY- GERM CELL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3918 CMU0127 -a : OVARY- GERM CELL TUMOR - BEP (BLEOMYCIN + ETOPOSIDE + CISPLATIN) ; DAYS 1, 8, 15 - BLEOMYCIN 30 UNITS/WK IV, ETOPOSIDE 100 MG/M 2/DAY IV ; DAYS 1-5 - CISPLATIN 20 MG/M 2/DAY IV ; REPEAT EVERY 21 DAYS 3-4 CYCLES MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
3919 CMU0127 -b : OVARY- GERM CELL TUMOR - EP ( ETOPOSIDE + CARBOPLATIN) ; DAY 1 - CARBOPLATIN 400 MG/M 2 IV ON DAYS 1-3 ; REPEAT EVERY 28 DAYS FOR THREE CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
3920 CMU0128 : GESTATIONAL TROPHOBLAST DISEASES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3921 CMU0128 -a : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (5 DAYS REGIMEN) ; DAYS 1-5 - MTX 0.4 MG/KG/DAY IV OR IM FOR 5 DAYS, NOT TO EXCEED 25 MG/DAY ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3922 CMU0128 -b : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (8-DAY ALTERNATING REGIMEN) ; DAYS 1, 3, 5, AND 7 - MTX 1 MG/KG IM, ; DAYS 2, 4, 6, AND 8 - FOLINIC ACID 15 MG ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
3923 CMU0128 -c : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE + FOLINIC ACID ; DAY 1 - MTX 100 MG/M 2 IVP, THEN 200 MG/M 2 INFUSION ; DAY 2 - FOLINIC ACID 15 MG IM/PO Q12H FOR 4 DOSES ; REPEAT CYCLE EVERY 18 DAYS MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
3924 CMU0128 -d : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE - WEEKLY ; MTX 30-50 MG/M 2 IM WEEKLY MEDICAL ONCOLOGY 1400 1400 1400 1400 1400 1400 1400 1400
3925 CMU0128 -e : GESTATIONAL TROPHOBLAST DISEASES - ACT-D ; ACT-D 10-13 MCG/KG OR 0.5-MG FLAT DOSE IV QD FOR 5D ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
3926 CMU0128 -f : GESTATIONAL TROPHOBLAST DISEASES - ACTINOMYCIN ; ACTINOMYCIN 1.25 MG/M 2 IV ; REPEAT EVERY 2 WEEKS MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
3927 CMU0128 -g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (COMPLETE) ; DAY 1 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, MTX - 300 MG/M2 IV ; DAY 2 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, LEUCOVORIN - 15 MG PO/IM Q12H 4 DOSES ; DAY 8 - VINCRISTINE - 0.8 MG/M2 IV, CYCLOPHOSPHAMIDE - 600 MG/M2 IV ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
3928 CMU0129 : TESTICULAR CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3929 CMU0129 -a : TESTICULAR CANCER - EP ; DAYS 1-5 - ETOPOSIDE 100MG/M2, CISPLATIN 20MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
3930 CMU0129 -b : TESTICULAR CANCER - BEP ; DAYS 1-5 - CISPLATIN 20MG/M2, ETOPOSIDE 100MG/M2 ; DAYS 1, 8, AND 15 OR DAYS 2, 9, OR 16 - BLEOMYCIN 30 UNITS IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
3931 CMU0129 -c : TESTICULAR CANCER - VIP ; DAY 1 (BEFORE IFOSFAMIDE) - MESNA 120MG/M2 IV ; DAYS 1-5 - ETOPOSIDE 75MG/M2 IV, MESNA 1, 200MG/M2 IV, IFOSFAMIDE 1, 200MG/M2 IV + CISPLATIN 20MG/M2. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
3932 CMU0130 : PROSTATE CANCERPROSTATE CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3933 CMU0130 -a : PROSTATE CANCER - DOCETAXEL + PREDNISONE ; DAY 1 - DOCETAXEL 75MG/M2 IV, PREDNISONE 5MG ORALLY TWICE DAILY. ; ONCE EVERY 3 WEEKS, REPEAT FOR UP TO 10 CYCLES IF TOLERATED MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
3934 CMU0130 -c : PROSTATE CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
3935 CMU0131 : FEBRILE NEUTROPENIA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3936 CMU0131 -a : FEBRILE NEUTROPENIA - FIRST-LINE MONOTHERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G ; CEFEPIME 2 G ; MEROPENEM 1 G ; IMIPENEM-CILASTATIN 500 MG MEDICAL ONCOLOGY 14200 14200 14200 14200 14200 14200 14200 14200
3937 CMU0131 -b : FEBRILE NEUTROPENIA - SECOND-LINE DUAL THERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G IV PLUS AN AMINOGLYCOSIDE ; MEROPENEM 1 G IV PLUS AN AMINOGLYCOSIDE ; IMIPENEM-CILASTATIN 500 MG IV PLUS AN AMINOGLYCOSIDE MEDICAL ONCOLOGY 20500 20500 20500 20500 20500 20500 20500 20500
3938 CMU0132 : THYROID CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3939 CMU0132 -a : THYROID CANCER - SORAFENIB ; SORAFENIB 400 MG PO BID MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
3940 CMU0132 -b : THYROID CANCER - SUNITINIB ; SUNITINIB 50 MG MEDICAL ONCOLOGY 29900 29900 29900 29900 29900 29900 29900 29900
3941 CMU0132 -c : THYROID CANCER - PAZOPANIB MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
3942 CMU0132 -d : THYROID CANCER - DOXORUBICIN ; DOXORUBICIN 60 MG/M2 AS MONOTHERAPY OR IN COMBINATION WITH CISPLATIN 40 MG/M2 MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
3943 CMU0133 : THYMOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3944 CMU0133 -a : THYMOMA - CAP ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 50MG/M2 IV, CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 8 CYCLES. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
3945 CMU0133 -b : THYMOMA - CAPP ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV ; DAYS 1-3 - CISPLATIN 30MG/M2 IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 ; DAYS 1-5 - PREDNISONE 100MG. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
3946 CMU0133 -c : THYMOMA - ADOC ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 40MG/M2 IV ; DAY 3 - VINCRISTINE 0.6MG/M2 IV ; DAY 4 - CYCLOPHOSPHAMIDE 700MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 5 CYCLES. MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
3947 CMU0133 -d : THYMOMA - PE ; DAY 1 - CISPLATIN 60MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 120MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 8 CYCLES. MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
3948 CMU0133 -e : THYMOMA - VIP ; DAYS 1-4 - ETOPOSIDE 75MG/M2 IV, IFOSFAMIDE 1.2G/M2 IV, CISPLATIN 20MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
3949 CMU0133 -f : THYMOMA - CARBOPLATIN+PACLITAXEL ; DAY 1 - PACLITAXEL 225MG/M2 IV, CARBOPLATIN AUC = 6 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 6 CYCLES. MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
3950 CMU0134 : BRAIN CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3951 CMU0134 -i : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3952 CMU0134 -i-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - COMBINATION PCV (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY. ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY. ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3953 CMU0134 -i-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (7 WEEKS) ; DAYS 1-49 - TEMOZOLOMIDE 75MG/M2 ORALLY. ; REPEAT CYCLE EVERY 11 WEEKS (7 WEEKS ON/4 WEEKS OFF) FOR 6 CYCLES. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
3954 CMU0134 -i-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; TEMOZOLOMIDE MONTHLY 5-DAY COURSES AT DOSES OF 180 - 200MG/M2/DAY MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3955 CMU0134 -i-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (3 WEEKS) ; DAYS 1-21 - TEMOZOLOMIDE 75MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 28 DAYS. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
3956 CMU0134 -ii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMASSYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3957 CMU0134 -ii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 4 WEEKS UNTIL DISEASE PROGRESSION OR FOR UP TO 24 CYCLES. MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3958 CMU0134 -ii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV WITH DEFERRED RT (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3959 CMU0134 -ii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3960 CMU0134 -ii-c-1 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
3961 CMU0134 -ii-c-2 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - ADJUVANT TEMOZOLOMIDE - PRECEEDED BY CONCURRENT TEMOZOLOMIDE (WITH RT) ; TEMOZOLOMIDE 150-200MG/M2/DAY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3962 CMU0134 -ii-d : ADJUVANT TEMOZOLOMIDE MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3963 CMU0134 -ii-e : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV FOR 1P19Q CO-DELETED (WITH RADIOTHERAPY) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. FOR 6 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
3964 CMU0134 -iii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3965 CMU0134 -iii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
3966 CMU0134 -iii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - ADJUVANT TEMOZOLOMIDE (PRECEEDED BY CONCURRENT TEMOZOLZMIDE) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3967 CMU0134 -iii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (POST RT) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3968 CMU0134 -iii-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (200MG) WITH STANDARD RT ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2, ORALLY MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
3969 CMU0134 -iv : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3970 CMU0134 -iv-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + LOMUSTINE ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; ; DURING CRANIO-SPINAL RT MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
3971 CMU0134 -iv-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
3972 CMU0134 -v : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMAPRIMARY CNS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3973 CMU0134 -v-a : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPYHIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3974 CMU0134 -v-a-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + CYTARABINE ; DAY 1 - MTX 3.5G/M2 ; DAYS 2-3 - CYTARABINE 2G/M2 IV TWICE A DAY. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
3975 CMU0134 -v-a-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + LEUCOVORIN + IFOSFAMIDE + MESNA ; DAY 1 - MTX 4GM/M2 IV, ; DAYS 2-5 - LEUCOVORIN 20-25MG IV (UPTO 40MG) ; DAYS 3-5 - IFOSFAMIDE 1.5GM/M2 IV + MESNA 400MG IV MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
3976 CMU0134 -v-b : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY HIGH DOSE METHOTREXATE (MTX 2.5-4.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3977 CMU0134 -v-b-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + MTX + VINCRISTINE +PROCARBAZINE ; DAY 1 - RITUXIMAB 500MG/M2 IV ; DAY 2 - MTX 3.5MG/M2 IV PLUS VINCRISTINE 1.4MG/M2 ; PROCARBAZINE 100MG/M2/DAY ADMINISTERED FOR 7 DAYS WITH ODD-NUMBERED CYCLES MEDICAL ONCOLOGY 44000 44000 44000 44000 44000 44000 44000 44000
3978 CMU0134 -v-c : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY +/- MONOCLONAL ANTIBODY HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3979 CMU0134 -v-c-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE INDUCTION ; MTX 8G/M2 IV ; REPEAT EVERY 2 WEEKS UNTIL COMPLETE RESPONSE ACHIEVED OR MAX OF 8 CYCLES REACHED. ; MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
3980 CMU0134 -v-c-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE CONSOLIDATION ; MTX 8G/M2 IV ADMINISTERED ; REPEAT EVERY 2 WEEKS FOR 2 CYCLES. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
3981 CMU0134 -v-c-3-i : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 1-4) ; DAY 1 - MTX 8G/M2 IV, RITUXIMAB 375MG/M2 IV. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 27600 27600 27600 27600 27600 27600 27600 27600
3982 CMU0134 -v-c-3-ii : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 5-11) ; MTX 8G/M2 IV ADMINISTERED EVERY 4 WEEKS FOR 11 CYCLES. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
3983 CMU0134 -v-d : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3984 CMU0134 -v-d-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - INDUCTION ; DAY 1 - RITUXIMAB 375MG/M2 IV, FOLLOWED BY ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY, AFTER RITUXIMAB INFUSION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 22700 22700 22700 22700 22700 22700 22700 22700
3985 CMU0134 -v-d-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - MAINTANANCEDAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY. ; REPEAT CYCLE EVERY 4 WEEKS FOR 8 CYCLES. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
3986 CMU0134 -v-e : BRAIN CARCINOMA - MENINGIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3987 CMU0134 -v-e-1 : BRAIN CARCINOMA - MENINGIOMA - INTERFERON-ALFAINTERFERON-ALFA ; ALPHA-IFN 106 UNITS/M2 SC EVERY OTHER DAY FOR 4 WEEKS. ; REPEAT CYCLE EVERY 4 WEEKS. ; MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
3988 CMU0134 -v-e-2 : BRAIN CARCINOMA - MENINGIOMA -SOMATOSTATIN ANALOG ; SANDOSTATIN LAR DEPOT 10-30MG IM ; REPEAT EVERY 4 WEEKS. ; MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
3989 CMU0134 -v-e-3 : BRAIN CARCINOMA - MENINGIOMA - SUNITINIB ; DAYS 1-28 - SUNITINIB 50MG ORALLY DAILY. ; REPEAT CYCLE EVERY 42 DAYS. MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
3990 CMU0135 : HEAD AND NECK CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3991 CMU0135 -i : HEAD AND NECK CANCER - SQUAMOUS CELL CANCERS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3992 CMU0135 -i-a : HEAD AND NECK CANCER - HIGH DOSE CISPLATIN ; CISPLATIN 100MG/M2 IV + CONCURRENT RADIOTHERAPY; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
3993 CMU0135 -i-b : HEAD AND NECK CANCER - CARBOPLATIN + INFUSIONAL 5-FU ; DAYS 1-4 - 5-FU 600MG/M2/DAY AS CONTINUOUS IV I, CARBOPLATIN 70MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES (GIVEN CONCURRENTLY WITH RADIOTHERAPY). MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
3994 CMU0135 -i-c : HEAD AND NECK CANCER - 5-FU + HYDROXYUREA ; DAY 1 - HYDROXYUREA 1, 000MG ORALLY EVERY 12 HOURS (11 DOSES/CYCLE), 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
3995 CMU0135 -i-d : HEAD AND NECK CANCER - CISPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 30MG/M2 IV (EVERY MONDAY), ; DAY 2 - CISPLATIN 20MG/M2 IV (EVERY TUESDAY). ; REPEAT CYCLE EVERY WEEK FOR 7 CYCLES, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
3996 CMU0135 -i-e : HEAD AND NECK CANCER - CISPLATIN + INFUSIONAL 5-FU ; DAY 1 - CISPLATIN 60MG/M2 OVER ; DAYS 1-5 - 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
3997 CMU0135 -i-f : HEAD AND NECK CANCER - CARBOPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 40-45MG/M2, CARBOPLATIN 100MG/M2 ; REPEAT CYCLE EVERY WEEK FOR 8 CYCLES, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
3998 CMU0135 -i-g : HEAD AND NECK CANCER - WEEKLY CISPLATIN ; CISPLATIN 40MG/M2 IV PER WEEK MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
3999 CMU0135 -i-h : HEAD AND NECK CANCER - CISPLATIN (FOR HIGH RISK OROPHARYNGEAL CARCINOMA) ; DAYS 1, 22, AND 43 - CISPLATIN 100MG/M2 IV + RADIOTHERAPY. MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
4000 CMU0135 -i-i : HEAD AND NECK CANCER - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV, ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV. ; REPEAT EVERY 3 WEEKS FOR UP TO 4 CYCLES. MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
4001 CMU0135 -ii : HEAD AND NECK CANCER - NASOPHARYNX CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4002 CMU0135 -ii-a : NASOPHARYNX CANCER - CONCURRENT CISPLATIN FOLLOWED BY CONCURRENT CISPLATIN +5FUC ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4003 CMU0135 -ii-a-1 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN (FOLLOWED BY CONCURRENT CISPLATIN +5FU) ; DAY 1 - CISPLATIN 100MG/M2 IV; PLUS RADIOTHERAPY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; FOLLOWED BY CONCURRENT CISPLATIN +5FU MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
4004 CMU0135 -ii-a-2 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN +5FU - PRECEEDED BY (CONCURRENT CISPLATIN 3 CYCLES) ; DAYS 1-4 - CISPLATIN 80MG/M2/DAY, 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
4005 CMU0135 -ii-b : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN FOLLOWED BY CONCURRENT CARBOPLATIN +5FU MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4006 CMU0135 -ii-b-1 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN - (FOLLOWED BY CONCURRENT CARBOPLATIN +5FU) ; DAY 1 - CARBOPLATIN AUC 6MG/MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
4007 CMU0135 -ii-b-2 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN +5FU - PRECEEDED BY (CONCURRENT CARBOPLATIN ) ; DAY 1 - CARBOPLATIN AUC 5MG/MIN/ML IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 14200 14200 14200 14200 14200 14200 14200 14200
4008 CMU0135 -ii-c : NASOPHARYNX CANCER - CONCURRENT CISPLATIN ; CISPLATIN 40MG/M2 ; REPEAT WEEKLY FOR 7 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
4009 CMU0135 -ii-d : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU FOLLOWED BY CISPLATIN ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4010 CMU0135 -ii-d-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU - FOLLOWED BY CISPLATIN AFTER 3 CYCLES ; DAY 1 - DOCETAXEL 70MG/M2 IV, CISPLATIN 75MG/M2 IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT EVERY WEEK FOR 3 CYCLES MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
4011 CMU0135 -ii-d-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 3 CYCLES OF DOCETAXEL + 5-FU ; DAY 1 - CISPLATIN 100MG/M2; ; REPEAT EVERY 3 WEEKS, TILL RADIATION MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
4012 CMU0135 -ii-e : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4013 CMU0135 -ii-e-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN - FOLLOWED BY CISPLATIN AFTER 2 CYCLES ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR TWO CYCLES MEDICAL ONCOLOGY 4100 4100 4100 4100 4100 4100 4100 4100
4014 CMU0135 -ii-e-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 2 CYCLES OF DOCETAXEL + CISPLATIN ; CISPLATIN 40MG/M2 IV ; WEEKLY CONCURRENT WITH RADIOTHERAPY. MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
4015 CMU0135 -ii-f : NASOPHARYNX CANCER - CISPLATIN + 5-FU ; DAY 1 - CISPLATIN 100MG/M2/DAY IV. ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION FOR 4 DAYS. ; REPEAT CYCLE EVERY 3 WEEKS FOR A MINIMUM OF 6 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
4016 CMU0135 -i-j : HEAD AND NECK CANCER - PACLITAXEL + CISPLATIN+ INFUSIONAL 5-FU ; DAY 1 - PACLITAXEL 175MG/M2 ; DAY 2 - CISPLATIN 100MG/M2 ; DAY 2-6 - 5-FU 500MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
4017 CMU0136 : RENAL CELL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4018 CMU0136 -a : RENAL CELL CARCINOMA - PAZOPANIB MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
4019 CMU0136 -b : RENAL CELL CARCINOMA - SUNITINIB MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
4020 CMU0136 -c : RENAL CELL CARCINOMA - SORAFENIB MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
4021 CMU0136 Ia : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
4022 CMU0136 Ib : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
4023 CMU0136 Ic : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - BEVACIZUMAB + IFN-ALPHA ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS + IFN-ALPHA. MEDICAL ONCOLOGY 70100 70100 70100 70100 70100 70100 70100 70100
4024 CMU0136 Id : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4025 CMU0136 IIa : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 39100 39100 39100 39100 39100 39100 39100 39100
4026 CMU0136 IIb : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
4027 CMU0136 IIc : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4028 CMU0136 IId : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
4029 CMU0136 IIe : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. MEDICAL ONCOLOGY 69600 69600 69600 69600 69600 69600 69600 69600
4030 CMU0136 IIIa : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
4031 CMU0136 IIIb : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. MEDICAL ONCOLOGY 69600 69600 69600 69600 69600 69600 69600 69600
4032 CMU0136 IIIc : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 39100 39100 39100 39100 39100 39100 39100 39100
4033 CMU0136 IIId : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - ERLOTINIB ; ERLOTINIB 150MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
4034 CMU0136 IIIe : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
4035 CMU0136 IIIf : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4036 CMU0137 : UNKNOWN PRIMARY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4037 CMU0137 -i : UNKNOWN PRIMARY - ADENOCARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4038 CMU0137 -i-a : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN + ETOPOSIDE ; DAY 1 - PACLITAXEL 200 MG/M 2 IV, CARBOPLATIN AUC 6 ; DAYS 1-10 - ETOPOSIDE 50 MG PO ALTERNATING WITH 100 MG DAILY ; REPEAT EVERY 21DAYS FOR 2-3 CYCLES; RESTAGE, CAN BE TREATED UPTO 8 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
4039 CMU0137 -i-b : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 200 MG/M 2, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
4040 CMU0137 -i-c : UNKNOWN PRIMARY - ADENOCARCINOMA - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 65MG/M2 IV, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
4041 CMU0137 -i-d : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + CISPLATIN ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
4042 CMU0137 -i-e : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + DOCETAXEL ; DAY 1 AND 8 - GEMCITABINE 1000MG/M2 IV OVER 30 MINUTES ; DAY 8 - DOCETAXEL 75MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR A MAXIMUM OF 6 CYCLES MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
4043 CMU0137 -i-f : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + IRINOTECAN ; DAYS 1 AND 8 - IRINOTECAN 100MG/M2 IV, GEMCITABINE 1000MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.RESTAGE EVERY 2-3 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
4044 CMU0137 -i-g : UNKNOWN PRIMARY - ADENOCARCINOMA - MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
4045 CMU0137 -i-h : UNKNOWN PRIMARY - ADENOCARCINOMA - CAPEOX ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAY 1-14 - CAPECITABINE 850-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 16 CYCLES. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
4046 CMU0137 -i-i : UNKNOWN PRIMARY - ADENOCARCINOMA - IRINOTECAN + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
4047 CMU0137 -ii : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4048 CMU0137 -ii-a : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - PACLITAXEL + CISPLATIN + 5-FU ; PACLITAXEL 175 MG/M 2 IV, ; DAY 2 - CISPLATIN 100 MG/M 2 IV, ; DAY 5-FU (5-FLUOROURACIL) 500 MG/M 2/DAY IV ; REPEAT EVERY 21D MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
4049 CMU0137 -ii-b : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
4050 CMU0137 -ii-c : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 6MG PER MIN/ML IV OVER 30 MINUTES + PACLITAXEL 200MG/M2 IV OVER 3 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES IN RESPONDING PATIENTS AND FOR 6 CYCLES MAXIMUM IN PATIENTS WITH STABLE DISEASE MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
4051 CMU0137 -ii-d : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + GEMCITABINE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
4052 CMU0137 -ii-e : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES. MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
4053 CMU0137 -ii-f : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV + CISPLATIN 60MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
4054 CMU0137 -ii-g : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV OVER 30 MINUTES + CARBOPLATIN AUC 5MG PER MIN/ML IV OVER 30 MINUTES. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
4055 CMU0137 -ii-h : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 60MG/M2 IV + CISPLATIN 80MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 2 CYCLES AND AN ADDITIONAL 4 CYCLES UNTIL DISEASE PROGRESSION IS DEMONSTRATED MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
4056 CMU0137 -iii : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4057 CMU0137 -ii-i : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
4058 CMU0137 -iii-b : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS - ETOPOSIDE + CISPLATIN ; DAYS 1-3 - ETOPOSIDE 100 MG/M 2 ; DAYS 2-3 - CISPLATIN 45 MG/M 2 IV ; REPEAT EVERY 28 DAYS MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
4059 CMU0137 -ii-j : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + FLUOROURACIL ; DAYS 1-5 - CISPLATIN 20MG/M2 IV ; DAYS 1-5 - FLUOROURACIL 700MG/M2/DAY IV VIA CONTINUOUS INFUSION OVER 24 HOURS. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
4060 CMU0138 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4061 CMU0138 -a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - GEMCITABINE + CISPLATIN ; DAYS 1 AND 8 - CISPLATIN 25MG/M2 IV, GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 4 CYCLES, RE-EVALUATE AND CONTINUE AN ADDITIONAL 4 CYCLES IF WARRANTED MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
4062 CMU0138 -b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV MEDICAL ONCOLOGY 4300 4300 4300 4300 4300 4300 4300 4300
4063 CMU0138 -c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - CAPECITABINE ; CAPECITABINE ORAL ; REPEAT EVERY 21 DAYS MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4064 CMU0139 : PANCREAS CARCINOMAPANCREAS CARCINOMA - MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4065 CMU0139 -i : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4066 CMU0139 -i-a : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 4 WEEKS FOR SIX CYCLES MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
4067 CMU0139 -ii : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4068 CMU0139 -ii-a : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - 5-FU + LEUCOVORIN ; DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
4069 CMU0139 -ii-b : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - GEMCITABINE & 5FU ; PRIOR TO CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 MONTHS. MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
4070 CMU0139 -ii-c : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - CONTINUOUS INFUSION 5-FU (WITH RADIATION) ; PRIOR TO CHEMORADIATION - ; DAYS 1-21 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1-28 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 6 WEEKS FOR 3 MONTHS. MEDICAL ONCOLOGY 21800 21800 21800 21800 21800 21800 21800 21800
4071 CMU0139 -iii : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - NEOADJUVANT THERAPY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4072 CMU0139 -iii-a : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - CAPECITABINECAPECITABINE ; CAPECITABINE ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 52 WEEKS. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4073 CMU0140 : PERI AMPULLARY CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4074 CMU0140 -a : PERI AMPULLARY CARCINOMA - 5-FU ; FLUOROURACIL 425 MG/M2 ADMINISTERED ON DAYS 1 TO 5 AND 29-33 MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
4075 CMU0141 : NEURO ENDOCRINE CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4076 CMU0141 -a : NEURO ENDOCRINE CARCINOMA - ALL NECS ARE COVERED UNDER ORGAN CANCERS. IF UNCOVERED - UNLISTED ONLY. MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4077 CMU0142 : SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4078 CMU0142 -i : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4079 CMU0142 -i-a : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST - IMATINIB ; IMATINIB 400MG ORALLY ONCE DAILY TO TWICE DAILY MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
4080 CMU0142 -ii : SARCOMA - SOFT TISSUE SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4081 CMU0142 -ii-a : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + DACARBAZINE (AD) ; DAYS 1-4 - DOXORUBICIN 60MG/M2 + DACARBAZINE 750MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 12100 12100 12100 12100 12100 12100 12100 12100
4082 CMU0142 -ii-b : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + IFOSFAMIDE + MESNA ; DAYS 1 AND 2 - DOXORUBICIN 30MG/M2/DAY IV, IFOSFAMIDE 3, 750MG/M2/DAY IV, MESNA 750MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
4083 CMU0142 -ii-c : SARCOMA - SOFT TISSUE SARCOMA - MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID) ; DAYS 1-3 - DOXORUBICIN 20MG/M2/DAY, IFOSFAMIDE 2, 500MG/M2/DAY, DACARBAZINE 300MG/M2/DAY IV ; DAYS 1-4 - MESNA 2, 500MG/M2/DAY IV FOR 84 TO 96 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 11300 11300 11300 11300 11300 11300 11300 11300
4084 CMU0142 -ii-d : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE + EPIRUBICIN + MESNA ; DAYS 1 AND 2 - EPIRUBICIN 60MG/M2/DAY IV ; DAYS 1-5 - IFOSFAMIDE 1.8G/M2/DAY IV + MESNA. ; REPEAT CYCLE EVERY 3 WEEKS FOR 5 CYCLES. MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
4085 CMU0142 -ii-e : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DOCETAXEL ; DAYS 1 AND 8 - GEMCITABINE 900MG/M2 IV ; DAY 8 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
4086 CMU0142 -ii-f : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + VINORELBINE ; DAYS 1 AND 8 - VINORELBINE 25MG/M2 IV, GEMCITABINE 800MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 15500 15500 15500 15500 15500 15500 15500 15500
4087 CMU0142 -ii-g : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DACARBAZINE ; DAY 1 - GEMCITABINE 1, 800MG/M2 IV + DACARBAZINE 500MG/M2 IV. ; REPEAT CYCLE EVER 2 WEEKS FOR A TOTAL OF 12 CYCLES; MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
4088 CMU0142 -ii-h : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN ; DOXORUBICIN 60-75MG/M2 IV ; ONCE EVERY 3 WEEKS MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
4089 CMU0142 -ii-i : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAYS 1-3 - IFOSFAMIDE 2, 000-3, 000MG/M2/DAY IV FOR 3 TO 4 DAYS + MESNA ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
4090 CMU0142 -ii-j : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAY 1 - IFOSFAMIDE 5, 000MG/M2 + MESNA 5, 000MG/M2 IV ; DAY 2 - MESNA 400-600MG/M2 IV ; IFOSFAMIDE, MESNA ; REPEAT EVERY 3 WEEKS MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
4091 CMU0142 -ii-k : SARCOMA - SOFT TISSUE SARCOMA - EPIRUBICIN ; EPIRUBICIN 160MG/M2 IV ; REPEAT EVERY 3 WEEKS MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
4092 CMU0142 -ii-l : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE ; DAYS 1 AND 8 - GEMCITABINE 1, 200MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
4093 CMU0142 -ii-m : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (I) ; DACARBAZINE 250MG/M2/DAY IV FOR 5 DAYS ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
4094 CMU0142 -ii-n : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (II) ; DACARBAZINE 800-1, 000MG/M2 IV ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
4095 CMU0142 -ii-o : SARCOMA - SOFT TISSUE SARCOMA - LIPOSOMAL DOXORUBICIN ; LIPOSOMAL DOXORUBICIN 30-50MG/M2 IV ; REPEAT EVERY 4 WEEKS. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
4096 CMU0142 -ii-p : SARCOMA - SOFT TISSUE SARCOMA - TEMOZOLOMIDE ; TEMOZOLOMIDE 200MG/M2 ORALLY TWICE DAILY FOR 5 DAYS, FOLLOWED BY 9 DOSES OF 90MG/M2 ORALLY ; REPEAT EVERY 4 WEEKS MEDICAL ONCOLOGY 4400 4400 4400 4400 4400 4400 4400 4400
4097 CMU0143 : PRIMITIVE NEURO ECTODERMAL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4098 CMU0143 -a : PRIMITIVE NEURO ECTODERMAL TUMOR - WEEKLY VINCRISTINE ; VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; FOR 5 TO 6 WEEKS MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
4099 CMU0143 -b : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + LOMUSTINE ; DURING CRANIOSPINAL RADIOTHERAPY (RT) ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; UP TO MAX 8 DOSES MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
4100 CMU0143 -c : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
4101 CMU0144 : ANAL CANAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
4102 CMU0144 -a : ANAL CANAL CANCER - 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY IV ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
4103 CMU0144 -b : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (I) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY. MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
4104 CMU0144 -c : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (II) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAY 1 - MITOMYCIN 12MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
4105 CMU0144 -d : ANAL CANAL CANCER - CISPLATIN + 5-FU ; DAYS 1-5 - 5-FU 1, 000MG/M2/DAY IV ; DAY 2 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
4106 CMU0145 : CA-PENIS MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
4107 CMU0145-a : CA-PENIS - CISPLATIN + 5-FU ; DAY 1 - 5 FU 1000mg/m2 D1-D4 and Day 1 - Cisplatin 75mg/m2 Every 4 weeks MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
4108 CMU0145-b : CA-PENIS -Paclitaxel; Paclitaxel 80 mg/m2 D1 every week MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
4109 CMU0145-c : CA-PENIS - Paclitaxel; Paclitaxel 175 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
5975 CMU0975 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5976 CMU0975 A : ALL LEUKEMIA( CHEMOTHERAPHY) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5977 CMU0975 A-I : CHRONIC MYELOID LEUKEMIA (CML) - CHRONIC MYELOID LEUKEMIA (CML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5978 CMU0975 A-II : ACUTE MYELOID LEUKEMIA (AML) - ACUTE MYELOID LEUKEMIA (AML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5979 CMU0975 A-II-a : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 1 - AGE MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
5980 CMU0975 A-I-i-a : CHRONIC MYELOID LEUKEMIA (CML) - IMATINIB - LOW TO INTERMEDIATE RISK - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
5981 CMU0975 A-II-b : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
5982 CMU0975 A-I-i-b : CHRONIC MYELOID LEUKEMIA (CML) - NILOTINIB - LOW TO INTERMEDIATE RISK - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
5983 CMU0975 A-II-c : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 2 - AGE MEDICAL ONCOLOGY 10900 10900 10900 10900 10900 10900 10900 10900
5984 CMU0975 A-II-d : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
5985 CMU0975 A-II-e : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
5986 CMU0975 A-II-f : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN (90MG) + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
5987 CMU0975 A-II-g : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
5988 CMU0975 A-II-h : ACUTE MYELOID LEUKEMIA (AML) - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 10800 10800 10800 10800 10800 10800 10800 10800
5989 CMU0975 A-II-i : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
5990 CMU0975 A-III : CHRONICLYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5991 CMU0975 A-I-ii : CHRONICMYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
5992 CMU0975 A-I-ii-a : CML - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - INDUCTION - 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY - CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M2 - OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY - OLDER THAN 60 Y) IV ON DAYS 1-3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1-21 (DAYS 1-7- OLDER THAN 60 Y) + L-ASPARAGINASE 6000 U/M 2 SC ON DAYS 5, 8, 11, 15, 18, AND 22 MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
5993 CMU0975 A-III-a-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 1 - DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY MEDICAL ONCOLOGY 1200 1200 1200 1200 1200 1200 1200 1200
5994 CMU0975 A-III-a-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 3 - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY MEDICAL ONCOLOGY 21800 21800 21800 21800 21800 21800 21800 21800
5995 CMU0975 A-III-a-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 4-8 - DAY 1; RITUXIMAB 500MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY. MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
5996 CMU0975 A-III-a-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - MAINTANANCE - RITUXIMAB - RITUXIMAB AT DOSE OF 375MG/M2 IV EVERY 2 MONTHS FOR 2 YEARS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
5997 CMU0975 A-III-b : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB DAY 1, 8, 15, AND 22 - DAY 1, 8, 15, AND 22; RITUXIMAB 375MG/M2/DAY IV. MEDICAL ONCOLOGY 85500 85500 85500 85500 85500 85500 85500 85500
5998 CMU0975 A-I-ii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
5999 CMU0975 A-III-c : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - CHLORAMBUCIL - DAYS 1-28; CHLORAMBUCIL 0.4MG/KG/DAY WITH AN INCREASE TO 0.8MG/KG ORALLY DAILY. REPEAT CYCLE EVERY 28 DAYS FOR 12 CYCLES MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
6000 CMU0975 A-I-ii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
6001 CMU0975 A-III-d-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLE -1) - DAY 0; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
6002 CMU0975 A-III-d-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLES 2-6) - RITUXIMAB 500MG/M2 ON DAY 1 AND BENDAMUSTINE - 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 32300 32300 32300 32300 32300 32300 32300 32300
6003 CMU0975 A-III-d-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (70MG) (CYCLE -1) - DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
6004 CMU0975 A-III-d-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (90 MG) (CYCLES 2-6) - DAY 1 - BENDAMUSTINE 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
6005 CMU0975 A-III-e : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG OR 500/M2 IV, DAYS 1-3; FLUDARABINE 25MG/M2/DAY IV PLUS CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 27200 27200 27200 27200 27200 27200 27200 27200
6006 CMU0975 A-III-f : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + RITUXIMAB (FR) - DAYS 1-5; FLUDARABINE 25MG/M2 IV, DAY 1; RITUXIMAB 50MG/M2 IV, DAY 3; RITUXIMAB 325MG/M2 IV, DAY 5; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH RITUXIMAB GIVEN AT A DOSE OF 375MG/M2 ON DAY 1 OF SUBSEQUENT CYCLES. MEDICAL ONCOLOGY 57800 57800 57800 57800 57800 57800 57800 57800
6007 CMU0975 A-III-g : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB + RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV MEDICAL ONCOLOGY 92700 92700 92700 92700 92700 92700 92700 92700
6008 CMU0975 A-III-h : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB WITHOUT RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
6009 CMU0975 A-III-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE + RITUXIMAB - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 88400 88400 88400 88400 88400 88400 88400 88400
6010 CMU0975 A-I-iii : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6011 CMU0975 A-I-iii-a : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG/M2)+ CYTARABINE - < 60 YEARS, DAYS 1-3; DAUNORUBICIN 90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
6012 CMU0975 A-I-iii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE + CLADRIBINE - AGE MEDICAL ONCOLOGY 10900 10900 10900 10900 10900 10900 10900 10900
6013 CMU0975 A-I-iii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
6014 CMU0975 A-I-iii-d : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG) + CYTARABINE - AGE >60 YEARS - DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
6015 CMU0975 A-I-iii-e : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE (HIGH DOSE) - DAYS 1-3; IDARUBICIN 12MG/M2, DAYS 1-6; HIGH-DOSE CYTARABINE 2G/M2 IV EVERY 12 HOURS, OR DAYS 1-4; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
6016 CMU0975 A-I-iii-f : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
6017 CMU0975 A-I-iii-g : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
6018 CMU0975 A-I-iii-h : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
6019 CMU0975 A-I-iii-i : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
6020 CMU0975 A-III-j : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
6021 CMU0975 A-II-j : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-5; DECITABINE 20MG/M2 IV FOR A 4-WEEK CYCLE. MEDICAL ONCOLOGY 26300 26300 26300 26300 26300 26300 26300 26300
6022 CMU0975 A-II-k : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS MEDICAL ONCOLOGY 81400 81400 81400 81400 81400 81400 81400 81400
6023 CMU0975 A-II-l : ACUTE MYELOID LEUKEMIA (AML) - HYDROXYUREA - AGE ?60 YEARS, HYDROXYUREA 10-70MG/KG/DAY ORALLY IN DIVIDED DOSES. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
6024 CMU0975 A-II-m : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - HIGH DOSE - AGE MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
6025 CMU0975 A-II-n : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + IDARUBICIN + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; IDARUBICIN 10MG/M2 IV. MEDICAL ONCOLOGY 89400 89400 89400 89400 89400 89400 89400 89400
6026 CMU0975 A-II-o : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + MITOXANTRONE + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; MITOXANTRONE 10MG/M2 IV. MEDICAL ONCOLOGY 42700 42700 42700 42700 42700 42700 42700 42700
6027 CMU0975 A-II-p : ACUTE MYELOID LEUKEMIA (AML) - FLUDARABINE + CYTARABINE + IDARUBICIN + GCSF -DAYS 1-5; FLUDARABINE 30MG/M2 IV OVER 0.5 HOURS, DAYS 1-5; CYTARABINE 2G/M2 IV OVER 4 HOURS, DAYS 0 TO POLYMORPHONUCLEAR RECOVERY (>0.5 X 109/L); G-CSF 5MCG/KG OR 300MCG/M2. (G-CSF MAY ALSO START ON DAY +6 UNTIL ENGRAFTMENT.) + DAYS 1-3; IDARUBICIN 10MG/M2 IV. MEDICAL ONCOLOGY 70100 70100 70100 70100 70100 70100 70100 70100
6028 CMU0975 A-II-q : ACUTE MYELOID LEUKEMIA (AML) - ETOPOSIDE +CYTARABINE+MITOXANTRONE - ETOPOSIDE +CYTARABINE+MITOXANTRONE, DAYS 1-6; ETOPOSIDE 80MG/M2 IV OVER 1 HOUR, DAYS 1-6; CYTARABINE 1G/M2 IV OVER 6 HOURS + DAYS 1-6; MITOXANTRONE 6MG/M2 IV BOLUS MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6029 CMU0975 A-II-r : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE SC - DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
6030 CMU0975 A-II-s : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS MEDICAL ONCOLOGY 81400 81400 81400 81400 81400 81400 81400 81400
6031 CMU0975 A-II-t : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - DAYS 1-5; DECITABINE 20MG/M2 IV EVERY 28 DAYS. MEDICAL ONCOLOGY 26800 26800 26800 26800 26800 26800 26800 26800
6032 CMU0975 A-IV : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6033 CMU0975 A-IV-i : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6034 CMU0975 A-IV-i-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 INDUCTION PHASE; INDUCTION; 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY; CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M 2 IF PATIENTS OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY IF PATIENTS OLDER THAN 60 Y) IV ON DAYS 1 - 3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1 - 21 (DAYS 1 - 7 IF PATIENTS OLDER THAN 60 Y); MEDICAL ONCOLOGY 14000 14000 14000 14000 14000 14000 14000 14000
6035 CMU0975 A-IV-i-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 - (3 WEEKS); DAY 1 - METHOTREXATE (MTX) INTRATHECALLY (IT), ETOPOSIDE 100MG/M2/DAY INTRAVENOUSLY (IV), IFOSFAMIDE 3.4G/M2/DAY IV; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY; DAYS 6 - 15 - FILGRASTIM 5G/KG/DAY SUBCUTANEOUSLY (SC) +/- IMATINIB; DAYS 8 AND 15 - CNS LEUKEMIA ONLY - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; MEDICAL ONCOLOGY 18000 18000 18000 18000 18000 18000 18000 18000
6036 CMU0975 A-IV-i-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 (3 WEEKS); DAY 1 - AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT + MTX 5G/M2 IV OVER 24 HOURS; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF PATIENT DOES NOT ACHIEVE COUNT RECOVERY WITHIN 2 WEEKS OF LAST DOSE OF PREVIOUS COURSE); DAYS 2 - 3 - LEUCOVORIN 75MG/M2 36 HOURS AFTER MTX, FOLLOWED BY 15MG/M2 IV OR ORALLY EVERY 6 HOURS FOR 6 DOSES + CYTARABINE 3G/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4 - 13 - FILGRASTIM 5G/KG/DAY SC MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
6037 CMU0975 A-IV-i-a-4 : ALL - PH(+) AYA - COG AALL-0031 REINDUCTION ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; DAYS 1 - 2 - DAUNORUBICIN 45MG/M2/DAY IV BOLUS; DAYS 1 - 21 - DEXAMETHASONE 6MG/M2/DAY ORALLY +/- IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 3 - 4 - CYCLOPHOSPHAMIDE 250MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES + MESNA 125MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4, 6, 8, 10, 12, 15, 17, 19, AND 21 - L - ASPARAGINASE 6, 000 IU/M2 INTRAMUSCULARLY (IM); DAYS 5 - 14 - FILGRASTIM 5G/KG/DAY SC; DAYS 8 AND 15 - VINCRISTINE 1.5MG/M2 IV; DAY 15 - MTX IT, HYDROCORTISONE IT, CYTARABINE IT. MEDICAL ONCOLOGY 26600 26600 26600 26600 26600 26600 26600 26600
6038 CMU0975 A-IV-i-a-5 : ALL - PH(+) AYA - COG AALL-0031 INTENSIFICATION; DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + MTX IV; DAYS 1-63 - IMATINIB ORAL; DAYS 2-3 - LEUCOVORIN ; DAY 8 - MTX IV; DAYS 9-10 - LEUCOVORIN; DAY 15 - MTX , HYDROCORTISONE , CYTARABINE - IT; DAYS 15-19 - ETOPOSIDE + CYCLOPHOSPHAMIDE + MESNA - IV; DAYS 20-29 - FILGRASTIM SC; DAYS 36-37 - CYTARABINE; DAY 37 - L - ASPARAGINASE IM +/- IMATINIB; DAYS 43-44 - CYTARABINE IV; DAY 44 - L - ASPARAGINASE IM +/- IMATINIB; MEDICAL ONCOLOGY 43500 43500 43500 43500 43500 43500 43500 43500
6039 CMU0975 A-IV-i-a-6 : ALL - PH(+) AYA - COG AALL-0031 MAINTENANCE CYCLES 1-4 (8 WEEKS); DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE + MTX IV; DAYS 1 - 5 - DEXA; DAYS 1 - 56 - IMATINIB; DAY 2 - LEUCOVORIN 36 HOURS AFTER MTX; DAYS 8, 15, AND 22 - MTX ORAL; DAYS 8 - 28 - 6-MP; DAY 29 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE IV; DAYS 29 - 33 - DEXA; DAYS 29 - 40 - IMATINIB; DAYS 36 - 40 - ETOPOSIDE + CYCLOPHOSPHAMIDE IV; DAYS 41 - 50 - FILGRASTIM SC; MEDICAL ONCOLOGY 37400 37400 37400 37400 37400 37400 37400 37400
6040 CMU0975 A-IV-i-a-7 : ALL - PH(+) AYA -COG AALL-0031 MAINTENANCE CYCLES 5-12 (8 WEEKS); CYCLE 5 ONLY - CRANIAL IRRADIATION 12 GY; DAY 1 - VINCRISTINE 1.5MG/M2 IV; DAYS 1 - 5 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 1 - 14 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 8, 15, AND 22 - MTX 20MG/M2/WEEK ORALLY; DAYS 8 - 28 - 6 - MP 75MG/M2/DAY; DAY 29 - VINCRISTINE 1.5MG/M2 IV; DAYS 29 - 33 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 29 - 42 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAY 36 - MTX 20MG/M2/WEEK ORALLY; DAYS 36 - 56 - 6 - MP 75MG/M2/DAY; DAYS 43 AND 50 - MTX 20MG/M2/WEEK ORALLY; MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
6041 CMU0975 A-IV-i-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 (CYCLES 1 AND 3 ONLY) - RITUXIMAB 375MG/M2 IV. MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
6042 CMU0975 A-IV-i-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4); HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65500 65500 65500 65500 65500 65500 65500 65500
6043 CMU0975 A-IV-i-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
6044 CMU0975 A-IV-i-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 MEDICAL ONCOLOGY 14100 14100 14100 14100 14100 14100 14100 14100
6045 CMU0975 A-IV-i-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
6046 CMU0975 A-IV-i-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
6047 CMU0975 A-IV-i-b-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
6048 CMU0975 A-IV-i-c-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
6049 CMU0975 A-IV-i-c-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
6050 CMU0975 A-IV-i-c-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
6051 CMU0975 A-IV-i-c-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
6052 CMU0975 A-IV-i-c-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
6053 CMU0975 A-IV-i-c-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
6054 CMU0975 A-IV-ii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6055 CMU0975 A-IV-ii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
6056 CMU0975 A-IV-ii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65500 65500 65500 65500 65500 65500 65500 65500
6057 CMU0975 A-IV-ii-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
6058 CMU0975 A-IV-ii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES MEDICAL ONCOLOGY 14100 14100 14100 14100 14100 14100 14100 14100
6059 CMU0975 A-IV-ii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
6060 CMU0975 A-IV-ii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
6061 CMU0975 A-IV-ii-a-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
6062 CMU0975 A-IV-ii-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 16400 16400 16400 16400 16400 16400 16400 16400
6063 CMU0975 A-IV-ii-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. MEDICAL ONCOLOGY 12700 12700 12700 12700 12700 12700 12700 12700
6064 CMU0975 A-IV-ii-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
6065 CMU0975 A-IV-ii-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
6066 CMU0975 A-IV-ii-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
6067 CMU0975 A-IV-ii-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
6068 CMU0975 A-IV-ii-c : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CORTICOSTEROIDS + TKIS - PRETREATMENT MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
6069 CMU0975 A-IV-iii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6070 CMU0975 A-IV-iii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 INDUCTION - CORTICOSTEROID PRE-PHASE - 1-7 DAYS BEFORE INDUCTION THERAPY; PREDNISONE 60MG/M2/DAY, 4-7 DAYS BEFORE INDUCTION THERAPY; MTX 15MG IT. INDUCTION I - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2/DAY + VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 50MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY, DAY 8; VINCRISTINE 2MG IV + L-ASPARAGINASE 6, 000IU/M2/DAY, DAYS 10 AND 12; L-ASPARAGINASE 6, 000IU/M2/DAY, DAY 15; VINCRISTINE 2MG IV, DAY 15; FOR GOOD EARLY RESPONDERS; CYCLOPHOSPHAMIDE 750MG/M2/DAY. MEDICAL ONCOLOGY 16500 16500 16500 16500 16500 16500 16500 16500
6071 CMU0975 A-IV-iii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 SALVAGE - DAYS 1-3; IDARUBICIN 12MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. MEDICAL ONCOLOGY 30200 30200 30200 30200 30200 30200 30200 30200
6072 CMU0975 A-IV-iii-a-3 : ALL - PH(-) AYA - GRAALL-2003 CONSOLIDATION - BLOCKS 1, 4, AND 7; - DAYS 1 AND 2; CYTARABINE 2G/M2/12 HOURS + DEXAMETHASONE 10MG/12 HOURS, DAY 3; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 7-13; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 2, 5, AND 8 - DAY 15; MTX 3G/M2 CONTINUOUS INFUSION + VINCRISTINE 2MG IV + 6-MP 60MG/M2/DAY, DAY 16; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 16-21; 6-MP 60MG/M2/DAY, DAYS 22-27; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 3, 6, AND 9 - DAY 29; MTX 25MG/M2/DAY, DAYS 29 AND 30; CYCLOPHOSPHAMIDE 500MG/M2/DAY + ETOPOSIDE 75MG/M2/DAY, DAY 31; FILGRASTIM TO MYELOID RECOVERY. TO BE APPROVED 3 TIMES (BLOCKS - 1, 2, 3; BLOCKS - 4, 5, 6; BLOCKS - 7, 8, 9 MEDICAL ONCOLOGY 32300 32300 32300 32300 32300 32300 32300 32300
6073 CMU0975 A-IV-iii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN COMPLETE REMISSION [CR] AFTER THE FIRST INDUCTION COURSE) - DAY 1; VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 30MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY MEDICAL ONCOLOGY 16300 16300 16300 16300 16300 16300 16300 16300
6074 CMU0975 A-IV-iii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN CR AFTER SALVAGE COURSE) - DAYS 1-3; IDARUBICIN 9MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. MEDICAL ONCOLOGY 28600 28600 28600 28600 28600 28600 28600 28600
6075 CMU0975 A-IV-iii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 MAINTENANCE MEDICAL ONCOLOGY 59800 59800 59800 59800 59800 59800 59800 59800
6076 CMU0975 A-IV-iii-b : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CNS THERAPY-TREATMENT OF PATIENTS WITH INITIAL CNS INVOLVEMENT MEDICAL ONCOLOGY 22200 22200 22200 22200 22200 22200 22200 22200
6077 CMU0975 A-IV-iii-v : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CCG-1961 MEDICAL ONCOLOGY 19200 19200 19200 19200 19200 19200 19200 19200
6078 CMU0975 A-IV-iv : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6079 CMU0975 A-IV-iv-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) INDUCTION MEDICAL ONCOLOGY 19000 19000 19000 19000 19000 19000 19000 19000
6080 CMU0975 A-IV-iv-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) CONSOLIDATION MEDICAL ONCOLOGY 17500 17500 17500 17500 17500 17500 17500 17500
6081 CMU0975 A-IV-iv-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 1, 3, 5, 7 - DAYS 1 - 3 - CYCLOPHOSPHAMIDE IV EVERY 12 HOURS + MESNA CONTINUOUS IV INFUSION STARTING 1 HOUR BEFORE CYCLOPHOSPHAMIDE UNTIL 12 HOURS AFTER COMPLETION OF CYCLOPHOSPHAMIDE; DAYS 1 - 4 AND 11 - 14 - DEXAMETHASONE ORALLY DAILY, +/-; DAYS 1 AND 8 - RITUXIMABIV; DAY 4 - DOXORUBICIN IV OVER 24 HOURS; DAYS 4 AND 11 - VINCRISTINE IV MEDICAL ONCOLOGY 64000 64000 64000 64000 64000 64000 64000 64000
6082 CMU0975 A-IV-iv-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 2, 4, 6, 8 - DAY 1 - METHOTREXATE IV OVER 2 HOURS FOLLOWED BY CONTINUOUS IV INFUSION OVER 22 HOURS FOLLOWED BY LEUCOVORIN IV EVERY 6 HOURS STARTING 12 HOURS AFTER COMPLETION OF MTX; DAYS 2 - 3 - CYTARABINE (IV OVER 2 HOURS EVERY 12 HOURS, +/-; DAYS 1 AND 8 - RITUXIMAB 375MG/M2 IV; CNS PROPHYLAXIS; DAY 2 - METHOTREXATE 12MG IT; DAY 8 - CYTARABINE 100MG IT. MEDICAL ONCOLOGY 59700 59700 59700 59700 59700 59700 59700 59700
6083 CMU0976 A : ALL LYMPHOMACHEMOTHERAPHY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6084 CMU0976 A-I : HODGKINS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6085 CMU0976 A-I-a : HODGKINSLYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
6086 CMU0976 A-I-b : HODGKINSLYMPHOMA - ESCALATED BEACOPP - DAY 1; CYCLOPHOSPHAMIDE 1, 250MG/M2 IV OVER 60 MINUTES + DOXORUBICIN 35MG/M2 IV PUSH, DAYS 1-3; ETOPOSIDE 200MG/M2 IV OVER 2 HOURS MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
6087 CMU0976 A-I-c : HODGKINSLYMPHOMA - ABVD + RITUXIMAB (CYLED EVERY 4 WEEKS) - MEDICAL ONCOLOGY 24300 24300 24300 24300 24300 24300 24300 24300
6088 CMU0976 A-I-d-i : HODGKINS LYMPHOMA - ABVD + RITUXIMAB (1 CYCLE - WEEKLY RITUXIMAB 4 DOSES) FOLLOWED BY ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV FOR CYCLE 1 ONLY. REPEAT ABVD CYCLE EVERY 4 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION (OR ) 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION MEDICAL ONCOLOGY 87200 87200 87200 87200 87200 87200 87200 87200
6089 CMU0976 A-I-d-ii : HODGKINS LYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
6090 CMU0976 A-I-e-i : HODGKINS LYMPHOMA - CHOP + RITUXIMAB - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV, REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
6091 CMU0976 A-I-e-ii : HODGKINS LYMPHOMA - CHOP - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
6092 CMU0976 A-I-f-i : HODGKINS LYMPHOMA - CVP +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22000 22000 22000 22000 22000 22000 22000 22000
6093 CMU0976 A-I-f-ii : HODGKINS LYMPHOMA - CVP - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
6094 CMU0976 A-I-g : HODGKINSLYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 7 DAYS FOR 4 WEEKS WITH OR WITHOUT MAINTENANCE RITUXIMAB (375MG/M2 IV ONCE WEEKLY FOR 4 WEEKS EVERY 6 MONTHS FOR UP TO 2 YEARS) MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
6342 CMU1259 : Bone marrow aspiration of biopsy MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
6430 CMU1296-I : CT for CA Breast -Weekly Paclitaxel for Adjuvant Therapy Paclitaxel 80mg/m2 every week MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
6431 CMU1296-II : CT for CA Breast - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
6432 CMU1296-III : CT for CA Breast - Capecitabine for triple negative with residual disease after pre op taxane , alkylator, antracyclin. Capecitabine - 1000mg/m2 orally twice daily D1-D14 every 21 days MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
6433 CMU1296-IV : CT for CA Breast - Carboplatin + Gemcitabine for her2 negative, unresectable or stage 4 -M1 disease. Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6434 CMU1296-V : CT for CA Breast - Fulvestrant for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Fulvestrant 500 mg D1 D15 D28 then every 28 days. per dose13200 (39600 in cycle1 ) then 13200 per month - (per dose 45000 in cycle1 ) then 15000 per month MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
6435 CMU1296-VI : CT for CA Breast - Exemestane for ER-positive and or PR-positive, unresectable or stage -4-M1 disease. Exemestane 25 mg orally daily (q 3 monthsly) MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
6436 CMU1296-VII : CT for CA Breast - Lapatinib for her2 positive, unresectable or stage 4 -M1 disease. Lapatinib 500 mg BD orally , daily MEDICAL ONCOLOGY 15050 15050 15050 15050 15050 15050 15050 15050
6437 CMU1297 : CT for Metastatic bone malignancy - Zoledronic Acid Zoledronic acid 4 mg IV Monthly MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
6438 CMU1298-I : CT for CA Ovary - Cisplatin + Irinotecan for Recurrent Platinum-Sensitive Epithelial cancer Cisplatin 60mg/m2 D1 Irinotecan 60 mg/m2 D1 D8 D15 every 28 days MEDICAL ONCOLOGY 13050 13050 13050 13050 13050 13050 13050 13050
6439 CMU1298-II : CT for CA Ovary - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5-6 D1 every 28 days MEDICAL ONCOLOGY 17200 17200 17200 17200 17200 17200 17200 17200
6440 CMU1298-III : CT for CA Ovary - Etoposide for Recurrent Platinum-Resistant Epithelial Ovarian cancer Etoposide 50 mg/m2 OD D1-D21 every 28 days MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
6441 CMU1298-IV : CT for CA Ovary - Irinotecan Recurrent Epithelial Ovarian cancer Irinotecan 60 -90 mg/m2 D1 D8 every 21 days MEDICAL ONCOLOGY 10950 10950 10950 10950 10950 10950 10950 10950
6442 CMU1298-IX : CT for CA Ovary - Letrozole Letrozole 2.5 mg orally daily (3 months) MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
6443 CMU1298-V : CT for CA Ovary - Lipodox for Recurrent Platinum-Resistant Epithelial Ovarian cancer Lipodox 40 mg/m2 IV every 28 days MEDICAL ONCOLOGY 17950 17950 17950 17950 17950 17950 17950 17950
6444 CMU1298-VI : CT for CA Ovary - Carboplatin + Gemcitabine for Recurrent Platinum-Sensitive Epithelial Ovarian Cancer Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6445 CMU1298-VII : CT for CA Ovary - Cyclophosphamide for Recurrent Epithelial Ovarian Cancer Cyclophosphamide 50 mg/m2 OD D1-D21 every 28 days MEDICAL ONCOLOGY 2800 2800 2800 2800 2800 2800 2800 2800
6446 CMU1298-VIII : CT for CA Ovary - Tamoxifen Tamoxifem 20 mg orally daily (3 months) MEDICAL ONCOLOGY 1200 1200 1200 1200 1200 1200 1200 1200
6447 CMU1298-X : CT for CA Ovary - Single agent Carboplatin Carboplatin AUC 5-6 D1 every 21 days ( maximum -6 cycle) MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
6448 CMU1298-XI : CT for CA Ovary - Cisplatin Cisplatin 40 mg/m2 every week (maximum- 6 cycles) MEDICAL ONCOLOGY 4100 4100 4100 4100 4100 4100 4100 4100
6449 CMU1299-I : CT for Germ Cell Tumor - Carboplatin (AUC 7) Carboplatin AUC 7 every 21 days MEDICAL ONCOLOGY 7300 7300 7300 7300 7300 7300 7300 7300
6450 CMU1299-II : CT for Germ Cell Tumor - Etoposide + Cisplatin Cisplatin 20 mg/m2 IV D1-D5 Etoposide 100mg/m2 D1-D5 every 21 days MEDICAL ONCOLOGY 10860 10860 10860 10860 10860 10860 10860 10860
6451 CMU1299-III : CT for Germ Cell Tumor - Gemcitabine + Oxaliplatin Gemcitabine 1000mg/m2 D1 D8 Oxaiplatin 130mg/m2 D1 every 21 days MEDICAL ONCOLOGY 17500 17500 17500 17500 17500 17500 17500 17500
6452 CMU1299-IV : CT for Germ Cell Tumor - Gemcitabine + Paclitaxel Gemcitabine 1000mg/m2 D1 D8 D15 Paclitaxel 100 mg/m2 D1 D8 D15 every 28 days MEDICAL ONCOLOGY 17500 17500 17500 17500 17500 17500 17500 17500
6453 CMU1299-V : CT for Germ Cell Tumor - Paclitaxel + Ifosfamide + Cisplatin Paclitaxel 240 mg/m2 D1 Ifosfamide 1500mg/m2 D2-D5 Mesna 300 mg/m2 0h 4h 8h D2-D5 Cisplatin 25mg/m2 D2-D5 every 21 days MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
6454 CMU1299-VI : CT for Germ Cell Tumor - Vinblastin + Ifosfamide + Cisplatin Vinblastine 0.11 mg/kg IV D1-D2 Mesna 240mg/m2 0h 4h 8h D1-D5 Ifosfamide 1200mg/m2 D1-D5 Cisplatin 20 mg/m2 D1-D5 every 21 days MEDICAL ONCOLOGY 13600 13600 13600 13600 13600 13600 13600 13600
6455 CMU1300 : CT for Gestational Trophoblastic Neoplasia - Etoposide + Methotrexate + Dactinomycin + Cisplatin Etoposide 100mg/m2 IV D1 D2 D8 Dactinomycin 0.5 mg IV push D1 D2 Methotrexate 300 mg /m2 D1 Leucovorin 15 mg PO every 12 hrs for 4 doses Cisplatin 75mg/m2 D8 every 2 weeks MEDICAL ONCOLOGY 12750 12750 12750 12750 12750 12750 12750 12750
6456 CMU1301 : CT for Cervical Cancer - Carboplatin + Paclitaxel (recurrent or metastatic) Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
6457 CMU1302-I : CT for Endometrial Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
6458 CMU1302-II : CT for Endometrial Cancer - Cisplatin + Doxorubicin Doxorubicin 60 mg/m2 D1 Cisplatin 50mg/m2 every 3 weeks MEDICAL ONCOLOGY 4410 4410 4410 4410 4410 4410 4410 4410
6459 CMU1302-III : CT for Endometrial Cancer - Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5 D1 every 28 days MEDICAL ONCOLOGY 17200 17200 17200 17200 17200 17200 17200 17200
6460 CMU1302-IV : CT for Endometrial Cancer - Carboplatin + Gemcitabine Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8 Gemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 5-6 D1 only every 3 weeks MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6461 CMU1302-V : CT for Endometrial Cancer - Anastrozole 1 mg orally daily (for 3 months) MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
6462 CMU1303 : CT for Vulvar Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5 D1 every 21 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6463 CMU1304-I : CT for Ewing Sarcoma - Vincristine + Topotecan + Cyclophosphamide + Irinotecan + Temozolamide Vincristine 1.5mg/m2( day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) Given every 3 weeks Irinotecan 10-50 mg/sqM days 1-5 and days 8-12 Temozolamide 100mg/m2 days 1-5 of each cycle every 3 weeks MEDICAL ONCOLOGY 23160 23160 23160 23160 23160 23160 23160 23160
6464 CMU1304-II : CT for Ewing Sarcoma - VIE 4 cycles + VAC 6 cycles + VCD 4 cycles; VIE - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (day 1, 8 and 15) Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 3 weeks MEDICAL ONCOLOGY 9900 9900 9900 9900 9900 9900 9900 9900
6465 CMU1304-III : CT for Ewing Sarcoma - Vincristine + Adriamycin + Cyclophosphamide Ifosfamide + Etoposide Ifosfamide: 1800mg/m2 (days1-5) Etposide: 100mg/sq.m (days 1-5) Given every 2-3 weekly Vincristine 1.5mg/m2 (day 1 and 8) Adriamyicn: 75mg/m2 (day 1) Cyclophosphamide 1200mg/m2 (day 1) Given 2-3 weekly MEDICAL ONCOLOGY 12710 12710 12710 12710 12710 12710 12710 12710
6466 CMU1305-I : CT for Osteogenic Sarcoma - Doxorubicin + Cisplatin Cisplatin 100mg/m2 Doxorubicin 75mg/m2 given every 3 weeks MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
6467 CMU1305-II : CT for Osteogenic Sarcoma - Methotrexate + Doxorubicin + Cisplatin for Relapsed Osteogenic Sarcoma Cisplatin 120mg/sq.m Doxorubicin 75mg/m2 Methotrexate 8-12 gram/m2 Each cycle for 5 weeks MEDICAL ONCOLOGY 27000 27000 27000 27000 27000 27000 27000 27000
6468 CMU1305-III : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Adriamycin 25mg/m2 D1- D3 Cisplatin 33 mg/m2 D1-D3 every 21 days MEDICAL ONCOLOGY 29600 29600 29600 29600 29600 29600 29600 29600
6469 CMU1305-IV : CT for Osteogenic Sarcoma - OGS - 12 Ifosfamide 1800 mg/m2 D1-D5 Mesna 600mg/m2 0h 3h 6h 9h D1-D5 Cisplatin 33 mg/m2 D1-D3 every 21 days MEDICAL ONCOLOGY 28600 28600 28600 28600 28600 28600 28600 28600
6470 CMU1306 : CT for Soft Tissue Sarcoma - Ifosfamide + Adriamycin Doxorubicin 30mg/m2 D1 D2 Ifosfamide 2000 to 3000mg/m2 Mesna 400 to 600 mg/m2 0h 4h 8h D1 - D3 Every 21 days MEDICAL ONCOLOGY 13700 13700 13700 13700 13700 13700 13700 13700
6471 CMU1307-I : CT for Metastatic Melanoma - Dacarbazine + Cisplatin Dacarbazine 250mg/m2 D1-D5 Cisplatin 75 mg/m2 Every 21 days MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
6472 CMU1307-II : CT for Metastatic Melanoma - Temozolamide Temozolamide 200mg/m2 D1-D5 every 28 days MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
6473 CMU1307-III : CT for Metastatic Melanoma - Imatinib Tab Imatinib 400/800 mg daily MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
6474 CMU1308-I : CT for Anal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
6475 CMU1308-II : CT for Anal Cancer - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days MEDICAL ONCOLOGY 13300 13300 13300 13300 13300 13300 13300 13300
6476 CMU1309-I : CT for Colorectal Cancer - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
6477 CMU1309-II : CT for Colorectal Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 9570 9570 9570 9570 9570 9570 9570 9570
6478 CMU1309-III : CT for Colorectal Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days MEDICAL ONCOLOGY 18780 18780 18780 18780 18780 18780 18780 18780
6479 CMU1310 : CT for Esophageal Cancer - Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
6480 CMU1311-I : CT for Esophageal / Stomach Cancer - Irinotecan Irinotecan 60- 90 mg/m2 D1 D8 every 21 days MEDICAL ONCOLOGY 10930 10930 10930 10930 10930 10930 10930 10930
6481 CMU1311-II : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + 5 FU Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1000mg/m2 D1 D2 every 14 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6482 CMU1311-III : CT for Esophageal / Stomach Cancer - Docetaxel + Cisplatin + Capecitabine Docetaxel 40mg/m2 D1 Cisplatin 40 mg/m2 D1 Capecitabine 825mg/m2 twice daily every 14 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6483 CMU1311-IV : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + 5 FU Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Leucovorin 400mg/m2 D1 5FU 1200mg/m2 D1 D2 every 14 days MEDICAL ONCOLOGY 18500 18500 18500 18500 18500 18500 18500 18500
6484 CMU1311-V : CT for Esophageal / Stomach Cancer - Docetaxel + Oxaliplatin + Capecitabine Docetaxel 50mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Capecitabine 825 mg/m2 Twice daily every 14 days MEDICAL ONCOLOGY 18500 18500 18500 18500 18500 18500 18500 18500
6485 CMU1311-VI : CT for Esophageal / Stomach Cancer - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 9570 9570 9570 9570 9570 9570 9570 9570
6486 CMU1311-VII : CT for Esophageal / Stomach Cancer - Paclitaxel Paclitaxel 80mg/m2 every week MEDICAL ONCOLOGY 5990 5990 5990 5990 5990 5990 5990 5990
6487 CMU1312-I : CT for Hepatocellular Carcinoma - Doxorubicin (TACE) Doxorubicin 30-75 mg/m2 one course MEDICAL ONCOLOGY 22500 22500 22500 22500 22500 22500 22500 22500
6488 CMU1312-II : CT for Hepatocellular Carcinoma - Lenvatinib 12 mg daily MEDICAL ONCOLOGY 17000 17000 17000 17000 17000 17000 17000 17000
6489 CMU1313-I : CT for Panceratic Cancer - Gemcitabine + Nanopaclitaxel Gemcitabine 1000mg/m2 D1 D8 D16 Albumin bound Paclitaxel 125mg/m2 D1 D8 D15 every 28 days MEDICAL ONCOLOGY 28380 28380 28380 28380 28380 28380 28380 28380
6490 CMU1313-II : CT for Panceratic Cancer - 5FU + Leucovorin + Oxaliplatin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 Irinotecan 180mg/m2 every 14 days MEDICAL ONCOLOGY 18880 18880 18880 18880 18880 18880 18880 18880
6491 CMU1313-III : CT for Panceratic Cancer - Capecitabine + Gemcitabine Gemcitabine 1000mg/m2 D1 D8 D15 Capecitabine 830mg/m2 twice daily D1-D21 every 28 days MEDICAL ONCOLOGY 34130 34130 34130 34130 34130 34130 34130 34130
6492 CMU1314-I : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Irinotecan 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 9620 9620 9620 9620 9620 9620 9620 9620
6493 CMU1314-II : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 300 mg/m2 D 1(weekly till RT ends) MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
6494 CMU1314-III : CT for Gall Bladder Cancer / Cholangiocarcinoma - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days MEDICAL ONCOLOGY 8980 8980 8980 8980 8980 8980 8980 8980
6495 CMU1314-IV : CT for Gall Bladder Cancer / Cholangiocarcinoma - Oxaliplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 Oxaliplatin 100 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 17400 17400 17400 17400 17400 17400 17400 17400
6496 CMU1314-V : CT for Gall Bladder Cancer / Cholangiocarcinoma - Capecitabine + Irinotecan Capecitabine 1000mg/m2 D1-D14 Irinotecan 200 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
6497 CMU1314-VI : CT for Gall Bladder Cancer / Cholangiocarcinoma - 5FU + Leucovorin + Oxaliplatin 5 FU 1200mg/m2 D1 D2 Leucovorin 400mg/m2 D1 Oxaliplatin 85 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 13700 13700 13700 13700 13700 13700 13700 13700
6498 CMU1315 : CT for Gastointestinal stromal tumor - Sunitinib Sunitinb 37.5 mg once daily MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
6499 CMU1316 : CT for Mesothelioma - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 12150 12150 12150 12150 12150 12150 12150 12150
6500 CMU1317 : CT for Thymic Carcinoma - Cisplatin + Etoposide Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
6501 CMU1318-I : CT for CA Head & Neck - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6502 CMU1318-II : CT for CA Head & Neck - Docetaxel Docetaxel 20mg/m2 every week MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
6503 CMU1318-III : CT for CA Head & Neck - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
6504 CMU1318-IV : CT for CA Head & Neck - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 7690 7690 7690 7690 7690 7690 7690 7690
6505 CMU1318-IX : CT for CA Head & Neck - Paclitaxel Paclitaxel 80mg/m2 every week MEDICAL ONCOLOGY 5970 5970 5970 5970 5970 5970 5970 5970
6506 CMU1318-V : CT for CA Head & Neck - Etoposide + Cisplatin Etoposide 100mg/m2 D1 - D3 Cisplatin 75-100 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 9270 9270 9270 9270 9270 9270 9270 9270
6507 CMU1318-VI : CT for CA Head & Neck - Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 every 21 days MEDICAL ONCOLOGY 9000 9000 9000 9000 9000 9000 9000 9000
6508 CMU1318-VII : CT for CA Head & Neck - Gemcitabine + Cisplatin Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 12150 12150 12150 12150 12150 12150 12150 12150
6509 CMU1318-VIII : CT for CA Head & Neck - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 every 21 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6510 CMU1318-X : CT for CA Head & Neck - Paclitaxel Paclitaxel 175mg/m2 every 21 days MEDICAL ONCOLOGY 11800 11800 11800 11800 11800 11800 11800 11800
6511 CMU1318-XI : CT for CA Head & Neck - Carboplatin Carboplatin AUC 2 every week MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
6512 CMU1319 : CT for Renal Cell Cancer - Cabozantinib 60 mg od x 1 month every 4 weeks MEDICAL ONCOLOGY 13000 13000 13000 13000 13000 13000 13000 13000
6513 CMU1320-I : CT for Ureter / Urethra - Cisplatin + Methotrexate + Vinblastin Methotrexate 30mg/m2 D1 D8 Vinblastine 4 mg/m2 D1 D8 Doxorubicin 30 mg/m2 D2 Cisplatin 100 mg/m2 D2 Leucovorin 15 mg PO D2 D9 every 21 days MEDICAL ONCOLOGY 6750 6750 6750 6750 6750 6750 6750 6750
6514 CMU1320-II : CT for Ureter / Bladder / Urethra - Carboplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6515 CMU1320-III : CT for Ureter / Urethra - Cisplatin + Gemcitabine Gemcitabine 1000 mg/m2 D1 D8 Cisplatin 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 12150 12150 12150 12150 12150 12150 12150 12150
6516 CMU1320-IV : CT for Ureter / Urethra - Cisplatin + 5 FU 5 FU 1000mg/m2 D1-D4 Cisplatin 75mg/m2 D1 every 4 weeks MEDICAL ONCOLOGY 8180 8180 8180 8180 8180 8180 8180 8180
6517 CMU1320-IX : CT for Ureter / Urethra - Methotrexate + Vinblastin + Doxorubicin + Cisplatin Methotrexate 30mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicin 30 mg/m2 D2 Cuisplatin 70 mg/m2 D2 every 14 days MEDICAL ONCOLOGY 7540 7540 7540 7540 7540 7540 7540 7540
6518 CMU1320-V : CT for Ureter / Bladder / Urethra - Cisplatin + Paclitaxel Paclitaxel 175 mg /m2 D1 Cisplatin 75 mg /m2 D1 every 21 days MEDICAL ONCOLOGY 13300 13300 13300 13300 13300 13300 13300 13300
6519 CMU1320-VI : CT for Ureter / Bladder / Urethra - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
6520 CMU1320-VII : CT for Ureter / Bladder / Urethra - Gemcitabine + Paclitaxel Gemcitabine 2500 mg/m2 D1 Paclitaxel 150 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 15500 15500 15500 15500 15500 15500 15500 15500
6521 CMU1320-VIII : CT for Ureter / Bladder / Urethra - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days MEDICAL ONCOLOGY 9000 9000 9000 9000 9000 9000 9000 9000
6522 CMU1320-X : CT for Ureter / Bladder / Urethra - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6523 CMU1320-XI : CT for Ureter / Urethra - Paclitaxel Paclitaxel 80 mg/m2 D1 every week MEDICAL ONCOLOGY 6380 6380 6380 6380 6380 6380 6380 6380
6524 CMU1321-I : CT for CA Penis - Cisplatin + Paclitaxel Paclitaxel 175 mg/m2 D1 Cisplatin 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 13300 13300 13300 13300 13300 13300 13300 13300
6525 CMU1321-II : CT for CA Penis - Capecitabine Capecitabine 1000-1250 mg/m2 PO twice daily D1 -D14 every 21 days MEDICAL ONCOLOGY 7300 7300 7300 7300 7300 7300 7300 7300
6526 CMU1321-III : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6527 CMU1321-IV : CT for CA Penis - Paclitaxel + Carboplatin Paclitaxel 80 mg/m2 D1 Carboplatin AUC 2 D1 every week MEDICAL ONCOLOGY 7700 7700 7700 7700 7700 7700 7700 7700
6528 CMU1322-I : CT for CA Prostate - Docetaxel Docetaxel 60 mg/m2 D1 every 14 days MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
6529 CMU1322-II : CT for CA Prostate - Etoposide + Carboplatin Etoposide 100mg/m2 D1 - D3 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 7690 7690 7690 7690 7690 7690 7690 7690
6530 CMU1322-III : CT for CA Prostate - LHRH Agonist Leuprolide 22.5 ug every 3 months MEDICAL ONCOLOGY 15300 15300 15300 15300 15300 15300 15300 15300
6531 CMU1322-IV : CT for CA Prostate - Mitoxantrone + Prednisolone Mitoxantrone 12mg/m2 every 3 weeks Prednsiolone 10 mg daily MEDICAL ONCOLOGY 4200 4200 4200 4200 4200 4200 4200 4200
6532 CMU1322-V : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 80mg/m2 D1 Carboplatin AUC 2 D1 every week MEDICAL ONCOLOGY 7700 7700 7700 7700 7700 7700 7700 7700
6533 CMU1322-VI : CT for CA Prostate - Paclitaxel + Carboplatin Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
6534 CMU1322-VII : CT for CA Prostate - Docetaxel Docetaxel 20mg/m2 D1 every week MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
6535 CMU1322-VIII : CT for CA Prostate - Abiraterone 1000 mg + Prednisolone 10mg daily Once every month MEDICAL ONCOLOGY 13000 13000 13000 13000 13000 13000 13000 13000
6536 CMU1343A : CT for Low Grade Glioma - Vincristine + Carboplatin Vincristine 1.5mg/m2 (day 1, 8 and 15 for first 4 cycles and then only day 1 from cycle 5 to 17) Carboplatin 550mg/m2 every 3 weeks (all cycles) MEDICAL ONCOLOGY 5850 5850 5850 5850 5850 5850 5850 5850
6537 CMU1343B : CT for Low Grade Glioma - Vinblastin Vinblastine 6 mg/m2 every week MEDICAL ONCOLOGY 3340 3340 3340 3340 3340 3340 3340 3340
6538 CMU1344A : CT for Neuroblastoma - Cabroplatin + Etoposide + Cyclophosphamide + Doxorubicin Carboplatin 600mg/m2 Etoposide 100mg/m2 (days 1-5) Cyclophosphamide Doxorubicin MEDICAL ONCOLOGY 8590 8590 8590 8590 8590 8590 8590 8590
6539 CMU1344C : CT for Neuroblastoma - 13-cis retinoic acid 160mg/m2 per day for 2 weeks Each cycle given 4 weekly MEDICAL ONCOLOGY 2030 2030 2030 2030 2030 2030 2030 2030
6540 CMU1345B : CT for Rhabdomyosarcoma - Vincristine + Ifosfamide + Etoposide Vincristine 1.5mg/m2 (days 1, 8 and 15) Ifosfamide 1.8gm/m2 (days 1-5) Etoposide 100mg/m2 (days 1-5) Each cycle every 3 weeks MEDICAL ONCOLOGY 16200 16200 16200 16200 16200 16200 16200 16200
6541 CMU1346A : CT for Relapse Rhabdomyosarcoma - Vincristine + Topotecan + Cyclophosphamide and Vincristine + Adriamycin + Cyclophosphamide Vincristine 1.5mg/m2 (day 1) Topotecan 1.5mg/m2 (day 1-5) Cyclophosphamide 250mg/m2 (days 1-5) 3 - weekly Vincristine 1.5mg/m2 Adriamyicn 60mg/m2 Cyclophosphamide 600mg/m2 (all Day 1) Every 3 weeks. Cycles given in couplets MEDICAL ONCOLOGY 12420 12420 12420 12420 12420 12420 12420 12420
6542 CMU1347A : CT for Pediatric Acute Lymphoblastic Leukemia - Consolidation (Phase II, CNS Therapy Reinduction) MEDICAL ONCOLOGY 239650 239650 239650 239650 239650 239650 239650 239650
6543 CMU1347B-I : CT for Pediatric Acute Lymphoblastic Leukemia - ICICLE MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6544 CMU1347B-II : CT for Pediatric Acute Lymphoblastic Leukemia - BFM MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6545 CMU1347B-III : CT for Pediatric Acute Lymphoblastic Leukemia KLALL MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6546 CMU1347B-IV : CT for Pediatric Acute Lymphoblastic Leukemia - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841 MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6547 CMU1347C : CT for Pediatric Acute Lymphoblastic Leukemia - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly MEDICAL ONCOLOGY 2670 2670 2670 2670 2670 2670 2670 2670
6548 CMU1347D : CT for Ph+ve Pediatric Acute Lymphoblastic Leukemia for adult and paediatric - Dasatinib + chemo (to be used only with ALL therapy) MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
6549 CMU1348A : CT for Pediatric Lymphoblastic Lymphoma - Consolidation (Phase II, CNS Therapy Reinduction) MEDICAL ONCOLOGY 239650 239650 239650 239650 239650 239650 239650 239650
6550 CMU1348B-I : CT for Pediatric Lymphoblastic Lymphoma - ICICLE MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6551 CMU1348B-II : CT for Pediatric Lymphoblastic Lymphoma -BFM MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6552 CMU1348B-III : CT for Pediatric Lymphoblastic Lymphoma - KLALL MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6553 CMU1348B-IV : CT for Pediatric Lymphoblastic Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 841 MEDICAL ONCOLOGY 87000 87000 87000 87000 87000 87000 87000 87000
6554 CMU1348C : CT for Pediatric Lymphoblastic Lymphoma - 6 - Mercaptopurine 75mg/m2 daily Methotrexate 20mg/m2 weekly Vincristine 1.5mg/m2 monthly Intrathecal methotrexate 12 mg 3 monthly MEDICAL ONCOLOGY 2670 2670 2670 2670 2670 2670 2670 2670
6555 CMU1349B : CT for Pediatric Acute Myeloid Leukemia - Cytrabine 200mg/m2/day days 1-10 and Daunorubicin 50mg/m2 days 1, 3 and 5 Etposide 100mg/m2 days 1-5 MEDICAL ONCOLOGY 105240 105240 105240 105240 105240 105240 105240 105240
6556 CMU1350A : CT for Pediatric Acute Promyelocytic Leukemia - Consolidation MEDICAL ONCOLOGY 58800 58800 58800 58800 58800 58800 58800 58800
6557 CMU1350B : CT for Pediatric Acute Promyelocytic Leukemia - Induction MEDICAL ONCOLOGY 129400 129400 129400 129400 129400 129400 129400 129400
6558 CMU1350C : CT for Pediatric Acute Promyelocytic Leukemia - Maintenance (18 months total cost) MEDICAL ONCOLOGY 39300 39300 39300 39300 39300 39300 39300 39300
6559 CMU1351A : CT for Pediatric Hodgkins Lymphoma - COPDAC - Cyclophosphamide, Vincristine sulfate,Prednisone,Dacarbazine MEDICAL ONCOLOGY 9450 9450 9450 9450 9450 9450 9450 9450
6560 CMU1351B : CT for Pediatric Hodgkins Lymphoma - OPEA - Oncovin,Etoposide,Prednisone,doxorubicin hydrochloride MEDICAL ONCOLOGY 13000 13000 13000 13000 13000 13000 13000 13000
6561 CMU1352A : CT for Pediatric Hodgkins Lymphoma Relapse - ICE - ifosfamide, carboplatin, etoposide MEDICAL ONCOLOGY 14000 14000 14000 14000 14000 14000 14000 14000
6562 CMU1352B : CT for Pediatric Hodgkins Lymphoma Relapse - DECA - Dexamethasone, Etoposide, Cytarabine, Cisplatin MEDICAL ONCOLOGY 14000 14000 14000 14000 14000 14000 14000 14000
6563 CMU1352C : CT for Pediatric Hodgkins Lymphoma Relapse - IGVD MEDICAL ONCOLOGY 34000 34000 34000 34000 34000 34000 34000 34000
6564 CMU1353A : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (second month) MEDICAL ONCOLOGY 42570 42570 42570 42570 42570 42570 42570 42570
6565 CMU1353B : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Consolidation (first month) MEDICAL ONCOLOGY 42420 42420 42420 42420 42420 42420 42420 42420
6566 CMU1353C : CT for Pediatric Non Hodgkins Lymphoma - LMB (Lymphoma malign B) 89 - 96 - Maintenance MEDICAL ONCOLOGY 65780 65780 65780 65780 65780 65780 65780 65780
6567 CMU1353D : CT for Pediatric Non Hodgkins Lymphoma - MCP - Mitroxantrone,Chlorambucil,Prednisolone - 842 MEDICAL ONCOLOGY 98700 98700 98700 98700 98700 98700 98700 98700
6568 CMU1354A : Pediatric - Germ Cell Tumor / JEB MEDICAL ONCOLOGY 10650 10650 10650 10650 10650 10650 10650 10650
6569 CMU1355A : CT for Pediatric Hepatoblastoma - Carboplatin + Cisplatin + Doxorubicin MEDICAL ONCOLOGY 5590 5590 5590 5590 5590 5590 5590 5590
6570 CMU1355B : CT for Pediatric Hepatoblastoma - Cisplatin MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
6571 CMU1356A : CT for CA Lung - Docetaxel Docetaxel 75 mg/m2 D1 every 21 days MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
6572 CMU1356B : CT for CA Lung - Erlotinib Erlotinib 150 mg once daily MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
6573 CMU1356C : CT for CA Lung - Gefitnib Gefitinib 250 mg once daily MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
6574 CMU1356F : CT for CA Lung - Topotecan Topotecan 1.5 mg/m2 D1-D5 every 21 days MEDICAL ONCOLOGY 24600 24600 24600 24600 24600 24600 24600 24600
6575 CMU1356G : CT for CA Lung - Docetaxel Docetaxel 20 mg/m2 D1 every week MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
6576 CMU1356J : CT for CA Lung - Gemcitabine Gemcitabine 1000mg /m2 D1 D8 every 21 days MEDICAL ONCOLOGY 8980 8980 8980 8980 8980 8980 8980 8980
6577 CMU1356K : CT for CA Lung - Gemcitabine + Carboplatin Gemcitabine 1000 mg/m2 D1 D8 Carboplatin AUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
6578 CMU1356M : CT for CA Lung - Paclitaxel Paclitaxel 80mg/m2 every week MEDICAL ONCOLOGY 5990 5990 5990 5990 5990 5990 5990 5990
6579 CMU1356N : CT for CA Lung - Paclitaxel Paclitaxel 175mg/m2 every 21 days MEDICAL ONCOLOGY 11800 11800 11800 11800 11800 11800 11800 11800
6580 CMU1356P : CT for CA Lung - Paclitaxel + Cisplatin Paclitaxel 175 mg/m2 D1 Cisplatin 75mg/m2 D1 every 21 days MEDICAL ONCOLOGY 13300 13300 13300 13300 13300 13300 13300 13300
6581 CMU1356S : CT for CA Lung - Vinorelbine + Carboplatin Vinorelbine 25mg/m2 D1 D8 CarboplatinAUC 5-6 D1 every 21 days MEDICAL ONCOLOGY 17000 17000 17000 17000 17000 17000 17000 17000
6582 CMU1357A : CT for CA Cervix - Carboplatin Carboplatin AUC 2 every week MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
6583 CMU1358A : CT for primary CNS lymphoma - De-Angelis/MTR MEDICAL ONCOLOGY 36000 36000 36000 36000 36000 36000 36000 36000
6584 CMU1359A : GCT Testis - SA Carboplatin AUC 7 once every 3 weeks MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
6585 CMU1360A : CT for GCT of bone - Denosumab Denosumab 120 mg s/c D1, 8, 15 then every 28 days - 19800 per dose. Max 6 dose MEDICAL ONCOLOGY 18000 18000 18000 18000 18000 18000 18000 18000
6586 CMU1361A : GEP NET Neuroendocrine carcinoma - Temozolamide 150mg/m2 D9-14 + Capecitabine 1gm/me D1-14 every 28 days MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
6587 CMU1361B : GEP NET high grade Neuroendocrine carcinoma - Carboplatin AUC 5 + Etoposide 100mg/m2 D1-D3 every 21 days MEDICAL ONCOLOGY 13400 13400 13400 13400 13400 13400 13400 13400
6721 CMU1424A : Central lines in cancer patients for drug therapy -Silicon catheters in advanced cancer patients- Long term central lines MEDICAL ONCOLOGY 10000 0 0 0 0 0 0 0